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Abstract
Geometric uncertainties are inevitable in radiotherapy. These uncertainties in tumour
position are classified as systematic (Σ) and random (σ) errors. To account for these
uncertainties, a margin is added to the clinical target volume (CTV) to create the
planning target volume (PTV). The size of the PTV is critical for obtaining an optimal
treatment plan. Dose-based (i.e., physical) margin recipes as a function of systematic
and random errors based on coverage probability of a certain level of dose (90% or
95% of the prescription dose) have been published and widely used. However, with
a TCP-based margin it is possible to consider fractionation and the radiobiological
characteristics, especially the dose-response slope (γ50) of the tumour. Studies have
shown that the density of the clonogens decrease from the boundary of the gross tumour
volume (GTV). In such a scenario, dose that is lower than in the GTV should be
sufficient to eradicate these clonogens. Thus a smaller PTV margin with a gradual
dose fall-off can be used if the clonogen density in the GTV-CTV region is found to be
lower than in GTV. Studies have reported tiny tumour islets outside the CTV region.
These tiny tumour islets can be eradicated in some cases by the incidental dose outside
the PTV due to the nature of the photon beam irradiation, but if they are not in the
beam path the treatment outcome is compromised.
In this thesis, a Monte Carlo approach is used to simulate the effect of geometric
uncertainties, number of fractions and dose-response slope (γ50) using the ‘enhanced
Marsden’ TCP model on the treatment outcome. Systematic and random errors were
drawn from a pseudo-random number generator.The dose variations caused by tumour
displacements due to geometric uncertainties in the CTV are accumulated each fraction
on a voxel-by-voxel basis. Required margins for ≤ 1% mean population TCP (TCP pop)
for four-field (4F) brick and a highly conformal spherical dose distribution for varying
number of fractions, different γ50 and different combinations of Σ and σ are investigated.
It is found that TCP-based margins are considerably smaller than dose-based recipes in
most cases except for tumours with a steep dose-response slope (high γ50) and a small
number of fractions for both 4F and spherical dose distributions. For smaller geometric
uncertainties (Σ = σ=1 mm) margins can be close to zero for the 4F technique due
to high incidental dose outside the PTV. It is evident from the analyses that margins
depend on the number of fractions, γ50, the degree of dose conformality in addition to
i
Σ and σ. Ideally margins should be anisotropic and individualized, taking into account
γ50, number of fractions, and the dose distribution, as well as estimates of Σ and σ. No
single “recipe” can adequately account for all these variables.
Using an exponential clonogen distribution in the GTV-CTV region, possible PTV
margin reduction is demonstrated. Moreover, the effect of extra-CTV tumour islets is
studied using a prostate IMRT plan. The islets were randomly distributed around the
CTV with in a radius of 3 cm to represent different patients. The doses were rescaled up
to 102 Gy to obtain the dose-response curve (DRC). Interestingly, the obtained DRC
showed a biphasic response where 100% TCP could not be achieved just by escalating
the dose.
Another potential problem encountered in intensity-modulated radiotherapy (IMRT)
is the problems caused by the ‘interplay’ effect between the respiration-induced tumour
motion and the multileaf collimator (MLC) leaves movement during treatment. Sev-
eral dosimetric studies in the literature have shown that ‘interplay’ effects blur the
dose distribution by producing ‘hot’ and ‘cold’ dose inside the tumour. Most of these
studies were done in a phantom with ion chambers or films, which provide only 1D
or 2D dose information. If 3D dose information is available, a TCP based analysis
would provide a direct estimate of interplay on the clinical outcome. In this thesis, an
in-house developed dose model enabled us to calculate the 3D time-resolved dose con-
tribution to each voxel in the target volume considering the change in segment shapes
and position of the target volume. Using the model, delivered dose is accumulated in
a voxel-by-voxel basis inclusive of tumour motion over the course of treatment. The
effect of interplay on dose and TCP is studied for conventionally and hypofractionated
treatments using DICOM datasets. Moreover, the effect of dose rate on interplay is
also studied for single-fraction treatments. Simulations were repeated several times to
obtain mean population TCP (TCP pop) for each plan. The average variation observed
in mean dose to the target volumes were −0.76 ± 0.36% for the 20 fraction treatment
and −0.26±0.68%, −1.05±0.98% for the 3- and single-fraction treatments respectively.
For the 20-fraction treatment, the drop in TCP pop was −1.05± 0.39%, whereas for the
3 and single fraction treatments it was −2.8 ± 1.68% and −4.0 ± 2.84% respectively.
By reducing the dose rate from 600 to 300 MU/min for the single-fraction treatments;
the drop in TCP pop was reduced by ∼ 1.5%. In summary, the effect of interplay on
treatment outcome is negligible for conventionally fractionated treatments, whereas a
considerable drop in TCP is observed for the 3- and single-fraction treatments. Where
no motion management techniques such as tracking or gating are available for hypo-
fractionated treatments, reduced dose rate could be used to reduce the interplay effect.
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Chapter 1
Introduction
1.1 Radiotherapy
Radiotherapy is a branch of medicine which uses high-energy ionizing radiation to treat
cancer. The deposition of this energy in living tissues results in damage to the cells’
DNA which make them incapable of dividing and reproducing themselves. Although
radiation is received by normal and abnormal (tumor) cells, abnormal cells are more
susceptible to radiation as they divide more rapidly than normal cells. Over a period
of time with sufficient radiation dose the tumor cells die, whereas normal cells will
repair more effectively than tumor cells. The goal of radiotherapy is to maximize the
radiation dose to the tumor for an acceptably small damage to the normal tissues. This
is referred to as optimizing the therapeutic ratio.
There are two main types of radiation therapy, namely external beam radiotherapy
(EBRT) and brachytherapy, the former being more often used than latter. Both modal-
ities can occasionally be used together. For instance, in localized prostate, cervix and
breast cancer brachytherapy is commonly used to boost the dose to the gross tumor
volume. EBRT is generally delivered using a linear accelerator with qualities in the
range of 4-15 MV bremsstrahlung photons. The radiation beams are directed at the
tumor with the patient precisely positioned on the treatment couch. The prescribed
dose is then generally delivered using multiple beams from different orientations over
many fractions. Delivering the prescribed radiation dose by multiple beams signifi-
cantly reduces the volume of high dose delivered to the normal tissues by spreading
the radiation energy over a large volume of normal tissues. Hence, more dose can be
delivered to the tumor with fewer normal tissue complications. Figure 1.1 shows a
typical prostate radiotherapy treatment with five beams or fields, each from a different
direction.
Radiotherapy has evolved from simple square/rectangular field treatments into com-
plex 3D conformal radiotherapy (3DCRT) and later into even more complex intensity-
modulated radiotherapy (IMRT) treatments. With these advanced forms of radiother-
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apy, it is possible to reduce the dose to normal tissues substantially and hence more
dose can be delivered to the tumor for low normal tissue complication risk. Over the
years, the accuracy in dose calculation and ability to optimize radiotherapy treatments
with physical dose/biological cost functions have greatly improved due to significant
advancements in computer technology. It is only recently, however that treatment
delivery and patient positional accuracy been improved with image-guided radiother-
apy (IGRT). Nevertheless, patient positional uncertainties, accuracy in target volume
delineation, knowledge of clonogen density distribution inside and around the tumor
volumes and their consequences for treatment outcome are still areas of intense re-
search. In this thesis the effects of these factors on treatment outcome are investigated
using a mechanistic tumor control probability (TCP) model. Some of the methodology
and basic concepts used in radiotherapy planning and the problems associated with
them are described in the following sections.
Figure 1.1: Prostate plan with multiple fields
1.2 ICRU62 volume definition in radiotherapy
To enable consistent clinical practice, the International Commission on Radiation Units
and Measurements (ICRU) [1, 2] has defined volumes used in treatment planning and
for evaluation purposes. Figure 1.2 shows the volumes defined by ICRU62, according
to which
• Gross tumor volume (GTV) is gross palpable or visible/demonstrable extent and
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location of malignant growth.
• Clinical target volume (CTV) is an anatomical concept which contains GTV
and/or sub clinical microscopic disease which has to be eliminated in order to
achieve the aim of therapy.
• Planning target volume (PTV) is a geometric concept which takes into account
all the possible geometrical uncertainties and inaccuracies in the treatment so
that the prescribed dose is absorbed in the CTV.
PTV is comprised of internal target volume (ITV) and setup margin (SM),
which takes care of internal motion of the CTV and setup errors respectively.
• Treated volume (TV) is the volume encompassed by the isodose surface selected
by the radiation oncologist that is considered to achieve the purpose of treatment.
• Irradiated volume (IV) is the volume that receives a dose that is considered sig-
nificant in relation to normal tissue tolerance.
Figure 1.2: Volume definition in radiotherapy- ICRU62
1.3 Geometric uncertainties in radiotherapy
A course of radiotherapy is comprised of several procedures which are linked to others
as illustrated in figure 1.3. The first procedure is patient immobilization, by which
the patient is immobilized in the treatment position using a suitable immobilization
device. The patient is then scanned generally using a CT scanner; which provides a
3D model of the patient along with physical characteristics of tissues to be used for
3
dose calculation. tumor and critical structures are then contoured on the image slices
and 3D treatment planning is performed. At treatment time, the patient is positioned
on the treatment couch and aligned with the isocentre, occasionally with the help of
immobilization devices and the treatment is delivered. However due to inaccuracies in
the procedures involved, targeting the tumor with a high degree of precision is difficult.
Small errors will occur in each step of the process which will combine under the umbrella
concept of “geometric uncertainties” [3].These geometric uncertainties are categorized
as systematic (Σ) and random errors (σ). Systematic errors will have the same effect
on all fractions of the treatment while the effect of random errors may vary from
fraction to fraction. A schematic representation of the effect of geometric uncertainties
on the day-to-day position of the target volume is shown in fig 1.4. Figure 1.5 shows
the distribution of systematic and random errors drawn using a quasi-random number
generator in eight patients over a ten fraction treatment and their corresponding vector
sum of both (Σ & σ).
Figure 1.3: Radiotherapy process chain
4
Figure 1.4: Day-to-day variation in target position due to geometric uncertainties shown
relative to the reference position (solid circle).
5
Figure 1.5: Randomly generated systematic and random errors and their vector sum
for 8 different patients with 10 fractions each
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The sources of uncertainties in radiotherapy include inaccuracies in the delineation
of the gross tumor volume (GTV), determining the extent of microscopic tumor (CTV)
which should be given the therapeutic (i.e.prescribed) dose, organ/tumor inter-fractional
and intra-fractional morphological changes and setup errors. The inaccuracy in the def-
inition of the GTV may arise from the limitations in imaging modalities, which have a
limited resolution, especially in the cranio-caudal direction causing the partial-volume
effect [4]. Moreover, inter [5, 6] and intra-observer variations [6–10] in delineating the
target volumes are inevitably reflected in the accuracy of target volume delineation.
This uncertainty in target volume delineation belongs to the category of systematic
errors.
The second source of uncertainty is the definition of the extent of microscopic disease
spread i.e. CTV. Though modern treatment planning systems (TPS) offer a great deal
of flexibility and precision in delineating gross tumor (GTV) and normal tissues [11,12],
delineating the extent of CTV is one of the most challenging tasks for the radiation
oncologist. In many cases it is based on the experience of the radiation oncologist,
as currently available imaging techniques cannot show microscopic disease. The liter-
ature on this subject is vague and the CTV definition is considered ‘art’ rather than
‘science’ [13]. There are a few studies which address the extent of microscopic spread
of disease based on the surgical resection of specimens for prostate and head-and-neck
tumors. Giraud et al [14] have shown that a CTV margin of 6 to 8 mm is necessary to
cover 95% of the microscopic disease in head and neck tumors. Diaz et al have shown
in clinically localized prostatic cancer, 47% patients could have been treated excluding
seminal vesicles since the seminal vesicles were not involved, which in turn allows higher
dose to prostate with lesser rectal toxicity [15]. Though use of a generous CTV margin
will reduce the risk of missing microscopic disease, it will also increase the risk of normal
tissue complications. Therefore, improvement of the therapeutic ratio depends heavily
on precisely defining the GTV and CTV volumes.Other major sources of uncertain-
ties in radiotherapy include setup errors [16–18] and organ motion [13,19–22]. Several
studies have shown that setup errors can be reduced by using improved immobilization
techniques and setup protocols [16–18, 23–26]. With the advent of ‘on-board’ imaging
such as electronic portal imagers (EPIs) and cone-beam CT (CBCT), setup errors can
be precisely measured and corrected. However, the setup verification procedures can
only reduce the errors, not completely eliminate them (even the setup errors) due to
the limitations in the accuracy of EPIs or CBCT systems. For instance, the target
delineation errors cannot be estimated nor corrected by the setup verification proce-
dure. Moreover, organ motion cannot be accounted by setup verification procedures;
especially in cases where organ motion management is not used. Thus, the residual
errors can never be totally eliminated and the CTV always requires a margin. The most
common approach to account for these uncertainties is to expand the tumor volume
(CTV) with an additional margin (PTV). The size of this PTV margin is crucial in
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obtaining an optimal treatment plan. In the past, when there were no tools to measure
setup errors these margins were purely empirical. The advent of on-board imaging
tools made it possible to measure setup errors with high accuracy; they can provide
a detailed knowledge of the distribution of errors over a population of patients. Over
the last decade much attention has been paid to measuring and correcting geometric
errors which has paved the way for a new era in radiotherapy known as image-guided
radiotherapy (IGRT).
Respiration-induced tumor motion is another cause for concern in radiotherapy.
Respiration can contribute to both systematic (Σ) and random(σ) errors. Motion
can be accounted for by two methods if its magnitude is known [27, 28].The most
common approach is to expand the CTV with a margin for motion (ITV). This margin
is added essentially to make sure the CTV receives the prescription dose even when it is
moving.The second method is to model the breathing motion to accurately predict the
dose delivered to target and normal tissues over the breathing cycle [29,30]. While the
first approach is apparently simple to use, it is always not possible to use a sufficiently
large margin in the presence of nearby critical structures. In conventional, static-field
treatments, the fluence delivered by a field is spatially (except in the penumbra region)
and temporally invariant. Because of this invariance, the introduction of motion will
only produce a blurring effect of the dose at the edges of the target.This blurring
effect is similar to the effect of random errors (σ), but the blurring occurs in every
fraction as opposed to blurring over a large number of fractions due to random errors.
This effect can be easily managed by using a sufficient ITV margin. On the other
hand, fluence in intensity-modulated fields is spatially and temporally varying, generally
created by moving the MLC leaves into different positions over time. In IMRT, the
implicit condition is that the dose delivered by the different segments add up as planned
in the absence of movement of the target. In the presence of motion however, the dose
delivered to a moving target will not add up as planned potentially causing “hot” and
“cold” spots in the target volume. This effect is depicted in figure 1.6.
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Figure 1.6: Effect of tumor motion(left-to-right) in conventional and intensity-
modulated fields. Darker shades of grey represent higher fluence. For simplicity the
variation of fluence is shown in 1D. Solid and dotted lines represent dose across target
respectively while it is static and moving
While IMRT is preferable to conventional uniform-field radiotherapy for treating
some tumors due to its superior normal-tissue sparing capabilities [31–36, 36, 37] there
is still some concern about its use for lung tumors because of the dose blurring effect
caused by the ‘interplay’ effect. Several studies [38–45] have shown including the AAPM
report “The management of respiratory motion in radiation oncology report of AAPM
Task Group 76” [46] that treating tumours affected by respiratory motion with intensity
modulated fields remains a concern. Many of these studies doesn’t account target
deformation during motion and the effect of target deformation on dose distribution
remains unknown. Some of these studies have shown that the effect of interplay between
tumour motion and MLC leaves average out for treatments with many fractions (∼30
fractions) if a random respiratory phase is assumed from day to day. However, the effect
of tumour motion and MLC leaves remains a concern for hypofractionated treatments
and this has been emphasized by AAPM report 91 [46]. In addition, lung tumours
are the most affected by interplay effect since they tend to displace more than other
tumours such as liver or kidneys. Lung tumours are known to have a steep dose-
response curve and it indicates a small change in the dose could result in a large
change in the biological effect. Different patients have different patterns of breathing
including frequency, amplitude, different tumour size, MLC shapes and its weight in
the treatment fields and different number of treatment fractions. It is thus very difficult
to construct a mathematical model to predict the effect of interplay for a given pattern
of MLC movement on tumour control probability. In such a scenario, a computer
simulation model of the interplay between tumour motion and the MLC leaves for the
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given patient considering the radiobiological characteristics of the tumour (clonogen
density, radiosensitivity, dose-response curve), number of fractions and the MLC shapes
within each field will provide a valuable estimate of the impact of interplay effect on
tumour control.
1.4 Aims
1.4.1 PTV margins
Several research groups have proposed margin recipes based on the knowledge of the
distribution of geometric uncertainties in the patient population. Bel et al [47] have
proposed a margin of 0.7σ to account for random uncertainties alone based on dose
distribution of three and four rectangular field prostate treatment plans, so that the
minimum dose to the CTV will be 95% of the prescription dose. It should be noted that
this number of 0.7 corresponds to a specific beam arrangement and its applicability to
other beam arrangements is not valid. Antolok et al [48] recommended a margin of
1.65 times random uncertainties which guarantees a minimum CTV dose that is greater
than 95% of the minimum PTV dose, but this does not assume any specific beam
arrangements nor a specific penumbra profile. The effect of systematic uncertainties,
which has a substantial effect on the CTV dose has been ignored in both these studies.
Excluding systematic uncertainties results in under estimation of margins which leads to
frequent geometric miss of the CTV. In order to accurately model the effect of geometric
uncertainties on TCP which depends on knowing the dose that is exactly delivered to
the target volume, it is important to account the dose discrepancies caused by both
systematic and random uncertainties. Others [49–53] have considered both systematic
and random uncertainties in the margin calculation with different assumptions (% of
minimum CTV dose, % of CTV receiving the minimum prescribed dose, width of beam
penumbra and the gradient of dose fall off and rotational errors). McKenzie et al [49]
argued that the beam configuration should be taken into account while calculating
margins since the dose blurring on the edge of the target volume depends on the number
of beams and their orientation. Stroom et al [51] and van Herk et al [53] proposed
margin recipes based on coverage probabilities(probability of certain percentage of CTV
volume being covered by certain percentage of the prescription dose). van Herk et
al [53] suggested a recipe based on coverage probability which includes the width of
beam penumbra. However, this is hardly used in any clinic, rather the simplified
formula of 2.5Σ + 0.7σ is used. It is also important to note that different tumour
types behave differently to same amount of underdosage or overdosage depending on
their radiobiological characteristics. While most of these recipes are based on the
physical dose delivered to the target volume, a TCP based margin recipe will be more
appropriate since it accounts for the radiobiological characteristics of the tumour. van
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Herk et al [52] proposed a TCP based margin recipe for ≤ 1% drop in population
mean TCP for prostate radiotherapy. The σα assumed is 0.08 which corresponds to
a shallow dose-response curve which is a good approximation for prostate tumours.
They also emphasized the importance of including the rotational errors in the margin
calculation especially for prostate treatments where the seminal vesicles rotate about a
point that is distant from the prostate. They showed a reduction of 30% in probability
(from 90 to 60 %) in delivering minimum of 95% of the prescription dose in three field
prostate plans if the rotational errors were not included. It was shown by them that the
effect of rotational errors are highly dependent on position of the part of the tumour
that is rotating and the point about which it rotates. This severe underdosing is due
to the complex shape the target volume has when seminal vesicles are added to the
prostate tumour in margin determination. The rotational errors may differ from patient
to patient even for the same tumours and difficult to predict accurately. Hence, the
effect of rotational errors are not included in this thesis and also the aim is to compare
margins based on TCP and dose-based recipes and to get insight into the dependence
of margins on fraction number, dose-response curve of the tumour and geometrical
uncertainties. Jin et al [54] went a step further and included the microscopic disease
extension in the margin determination and concluded that the margins required for
a given set of geometric unceertainties are relatively much smaller if an exponentially
decreasing microscopic disease in the GTV-CTV region is assumed. For instance, the
margins calculated according to their recipe is 4 mm for Σ = 3, σ = 3 mm whereas it
is 10 mm according to the van Herk recipe of 2.5Σ + 0.7σ. It should be noted that
the metric assume d in both these recipes are different. Although margin recipes are
published which includes microscopic disease distribution, it is very difficult to use for
PTV determination for the patients as the knowledge of microscopic disease is not
adequate.
Sources of systematic errors include but are not limited to target delineation errors,
image blurring caused by organ motion which will shift the mean organ position, phan-
tom transfer error (error in transferring the patient position from imaging equipment
to the treatment machine) [55]. Sources of random errors include but again are not
limited to intra-fraction organ motion, daily setup errors and mechanical inaccuracies
of the linac [55]. Assuming that these individual errors are independent of each other
and have a Gaussian distribution, the combination of all systematic and all random
errors can be obtained by their quadratic sum as shown in equation (1.1)
Σ =
√
Σ2delineation + Σ
2
motion + Σ
2
transfer + Σ
2
setup (1.1a)
σ =
√
σ2organmotion + σ
2
patient−setup (1.1b)
The assumptions on which the margin recipes were derived and their corresponding
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recipes are given in table 1.1.
Table 1.1: Margin recipes based on geometric uncertainties
Group Recipe Comments/Criteria
Bel et al [47] 0.7σ Random errors only
Antolak and Rosen et al [48] 1.65σ Random errors only
Stroom et al [51] 2.0Σ +0.7σ 95% dose to 99% of CTV on
average
Van Herk et al [52] 2.5Σ +1.64(σ − σp) Minimum 95% dose to 90%
of the patients.σp is the stan-
dard deviation of the Gaus-
sian penumbra
McKenzie et al [49] 2.5Σ +β(σ − σp) Same as van Herk et al [52]
but includes fringe dose
Parker et al [50] Σ +
√
Σ2 + σ2 Minimum 95% dose and 100%
dose to 95% of the CTV
Van Herk et al [53] 2.5Σ +0.7σ -3mm ≤1% TCP loss in prostate pa-
tients
Jin et al [54]
√
(0.75σ)2 + (1.15Σ)2 2% drop at 90% TCP (mar-
gin added to GTV account-
ing for the decreasing density
of clonogens in GTV-CTV re-
gion)
Though there are several recipes, the van Herk et al [52] recipe is the most widely
used. In its simple form, the components for a given standard deviation of systematic
(Σ) and random(σ) errors are added linearly. It is based on the fact that systematic
and random errors have a different effect on the cumulative dose to the target. Sys-
tematic errors tend to shift the dose distribution while random errors blur the dose
distribution (for number of fractions ≥ 20). Many of these margin recipes are based on
the probability that for a given percentage of patients in a population, the CTV would
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receive a certain percentage of the prescription dose. However, margins based on TCP
would arguably be more appropriate than dose-based margins, as TCP-based margins
are directly linked to the treatment outcome. In addition, radiobiological models con-
sider the tumor dose-response characteristics. Van Herk et al [53] provided a margin
recipe for prostate tumors treated with a large number of fractions with the criterion
being ≤ 1% loss in population mean TCP (TCP pop). However, this recipe is only
applicable for prostate tumors treated with ≥20 fractions and cannot be applied for
tumors with other dose-response characteristics (γ50) and for hypofractionated treat-
ments. Brahme [56] concluded that higher tumor control could be achieved only if the
dose delivery accuracy was very high, especially for tumors with a steep dose-response
gradient (γ50). This implies that the same degree of uncertainty in dose delivery in
tumors with different γ50 will cause varying effects on tumor control. Moreover, hy-
pofractionated treatments are becoming more and more common especially for medi-
cally inoperable lung tumors where stereotactic ablative body radiotherapy (SABR) is
showing promising results [57]. It is thus imperative to understand the relationship be-
tween CTV-PTV margins, geometric uncertainties, fractionation, tumor dose-response
characteristics and treatment outcome i.e. TCP.
1.4.2 Microscopic disease distribution
As mentioned before, a margin is added to the GTV to create the CTV and thereby in-
clude the microscopic disease extension. In clinical practice this assumes that there are
no tumor cells outside the CTV and the density of the clonogenic cells is same as inside
the GTV. However, histopathological studies have shown that the tumor cell density
in the microscopic disease extension (MDE) region decreases with the distance from
the GTV boundary and may not be limited to the CTV [14, 58, 59]. The assumption
of equal clonogen density in the GTV-CTV region as in the GTV leads logically to the
need for a prescription dose to the CTV equal to that in the GTV. Conversely, in cases
where the density of the clonogenic cells decreases from the boundary of the GTV, the
resulting smaller number of clonogenic cells can be eradicated with less dose than that
prescribed to the GTV. This is depicted in figure 1.7 for the assumed(uniform clonogen
density) and possible (decreasing clonogen density) scenarios in the GTV-CTV region
and possible dose reduction in the CTV-PTV region. The reduced prescription dose in
the CTV-PTV region will in turn reduce the required PTV margin. Moreover due to
the nature of the external photon beam irradiation, considerable dose is deposited out-
side the PTV along the beam pathways. This incidental dose outside the PTV may be
sufficient to eradicate the low density clonogenic tumor cells outside the CTV [60–62].
PTV margins could be reduced if the clonogen density outside the GTV were known
and found to be lower than in the GTV. Only a few studies have quantified the extent
to which the PTV margin can be reduced given reduced clonogen density in the GTV-
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CTV region. Microscopic tumor islets have been found in 50% of NSCLC patients with
an average of 5 islets per patient varying from 1 to 3 mm in diametre [63]. Using this
data Siedschlag et al [64] have done a Monte Carlo simulation of the effect of MDE
on TCP for conventional and stereotactic treatments for various degrees of geomet-
ric uncertainties (systematic & random errors). They concluded that TCP improved
with increasing geometric uncertainties due to larger PTV margin used to account for
larger geometric uncertainties. They have aslo shown that MDE may not always be
eradicated by the penumbra or the PTV margins. This questions the decrease of the
PTV margin in IGRT treatments where extent of microscopic disease is not accurately
known. In another interesting study, Witte et al [65] reported that there are low den-
sity clonogenic islets in prostate cases which have been eradicated by the ‘incidental’
dose in some cases but not in others due to the different beam orientations used. These
studies provide useful insights into the effect of microscopic disease and low density
tumor islets on TCP. However, it would be useful to know how the TCP drops for a
given set of systematic (Σ) and random(σ) errors in the presence of tumor islets which
are outside the defined CTV. It would also be interesting to know the effect of gradient
in clonogen density in the GTV-CTV region on TCP as a function of PTV margin for
different Σ and σ.
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Figure 1.7: Assumed and possible scenarios of clonogen density in the GTV-CTV region
and possible PTV margin reduction. The possible and assumed scenarios of dose and
clonogen density are represented by dotted and solid lines respectively
1.4.3 Interplay effect in IMRT
These are several studies which have quantified the impact of interplay between MLC
movement and tumour motion. But most of these studies have reported the change in
the dose to tumour either on a single point or multiple points. However the tumour
control actually depends on the dose delivered to the each voxel of the tumour. More-
over, a TCP based analysis with appropriate dose-response slope for lung tumours and
fractionation will provide better insights into the effect of interplay on hypofractionate
treatments and conventional treatments.
A simulation model is presented in this thesis to obtain the change in the mean
population TCP(TCP pop due to interplay effect for the given patient treatment plan
considering the prescription dose, number of fractions and the radiobiological charac-
teristics of the tumour. A ray tracing model is used to find out the voxels that are
missed or irradiated by the primary radiation beam during tumour motion while also
considering the MLC shape at the given time interval. A dose calculation methodology
which account for tissue attenuation, MLC leakage and penumbra at the field edges is
presented. The effect of interplay for three different fraction 1, 3 and 20 are studied
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using the Marsden TCP model. The simulations are repeated several times for each pa-
tient to obtain TCP pop. As the dose rate increases, the treatment duration decreases.
As a result of this, the intrafraction dose blurring effect is reduced an the effect of
interplay can worsen. To study this two different dose rates are considered namely, 300
MU/min and 600 MU/min.
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Chapter 2
Tumor Control Probability
Cells are the basic structural, biological and functional unit of all living organisms. The
main constituents of the cell are the cytoplasm, which supports all metabolic functions
and the nucleus which contains the DNA. When cells are exposed to ionizing radiation
the standard physical interaction between the atoms of the cell and the radiation par-
ticles occur followed by possible biological damages to cell’s functions. The biological
damages are believed to occur due to the damage of the DNA, which is considered
to be the most critical target within the cell. The damage may occur directly or in-
directly depending upon the nature of the radiation. In direct action, the radiation
interacts directly with the atoms of the critical target (DNA) which leads to physical
and chemical events that result in biological damage. Direct action mainly occurs with
high LET (linear energy transfer) radiation whereas indirect action is responsible for
cell damage in low LET radiation such as x-rays and electrons. In indirect action the
radiation interacts with molecules and atoms (mostly water, as 80% of cell is composed
of it) within the cell to produce short lived but highly reactive free radicals such as
H2o
+ and OH. The free radicals in turn break the chemical bonds of the DNA which
leads to biological damage. The DNA has two strands formed in a double helical struc-
ture. SSBs are easier to repair than DSBs. The damages to the DNA can be caused in
the form of single strand breaks (SSBs) or double strand breaks (DSBs) The resulting
damage caused by radiation is divided in to three categories:
• Lethal damage, which is irreversible and irreparable and leads to cell death.
• Sub lethal damage is reparable if sufficient time is given unless additional damage
is made.
• Potentially lethal damage is repairable if the cells are allowed to remain in a
non-dividing state for a long time before additional damage is made.
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Figure 2.1: Cell survival curves for two different α/β ratios; 3 Gy (normal tissues) and
10 Gy (tumor) for single fraction.
2.1 Linear-Quadratic model based TCP calculation
It has been clinically and experimentally observed that the dose-response curves (DRC)
have a sigmoidal shape. A simple approach is to fit a mathematical function to this
curve, but such an approach will not be able to incorporate the changes in tumor
radiosensitivity and inhomogeneity in dose distribution. Radiobiological experiments
have shown that cell killing by radiation in certain cell lines can be described by a
linear-quadratic (LQ) model [66–68]. The α and β parameters (which are described in
the next section) in the LQ model characterize the initial slope and degree of curvature
respectively of the cell survival curve. Figure 2.1 shows the survival curves for two
different α/β ratios.
There are several models to quantify TCP including the Niemierko and Goitein
model [69] and the ‘Marsden’ model [70]. All these models are very similar to each
other and assume that tumors have a sigmoidal DRC and use the LQ model of cell kill
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with Poisson statistics to calculate the probability for clonogens to survive. The original
“Marsden” TCP model does not account for fractionation effects and it was modified
by Nahum and Sanchez-Nieto [71] to account for fractionation, which is refered to as
the “Enhanced Marsden” model in this thesis. The “Enhanced Marsden” model is used
in the entire work carried out in this thesis.
2.1.1 TCP calculation
The linear-quadratic (LQ) model assumes that there are two contributions of cell killing
by radiation namely ‘linear’ and ‘quadratic’ contributions. The ‘linear’ contribution
refers to damage produced by a single track of radiation whereas ‘quadratic’ contribu-
tion is produced by two different radiation tracks. The ‘linear’ contribution of cell kill
is directly proportional to the dose d and the ‘quadratic’ contribution is proportional
to d2.
The total cell kill by radiation is given as an exponential form of both ‘linear’ and
‘quadratic’ contributions. The amount of cell kill produced by single track radiation
is given by the α term in units of log cells killed per Gy and the amount of cell kill
produced by two different radiation tracks is given by the β term in units of log of cells
killed per Gy2. Assuming an initial clonogen number of N0 and Ns number of surviving
cells, the surviving fraction of cells can be written as SF = Ns/N0. The mean fraction
of cells surviving a single dose of d is given by equation (2.1).
ln(SF ) = −(αd+ βd2) (2.1)
which can be written as
SF = e−(αd+βd
2) (2.2)
for n fractions of d Gy each, the mean surviving fraction would become
SF = e−(αnd+βnd
2) (2.3)
Therefore, the average total number of cells surviving (Ns) can be calculated using
the LQ model by applying equation (2.3) as shown in (2.4)
Ns = N0e
−(αnd+βnd2) (2.4)
Since the ratio of α and β is better known than the individual α and β values,
equation (2.4) is rewritten as
Ns = N0e
−(αD(1+(d/α
β
)))
(2.5)
N0 can be calculated as ρclV . where ρcl is the clonogen density and V is the volume
of the tumor.
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Once the number of surviving cells are calculated, the probability for no single
clonogenic cell survival will be given by Poisson statistics.
The probability distribution of a random Poisson variable X is given by the equation
(2.6)
P (k) =
λke−λ
k!
(2.6)
where k is a discrete stochastic variable with values 0,1,2,3.... and λ is the mean
(expected) number of success in the time interval. In the context of radiotherapy, k=0
since the probability we are interested in is for “zero” surviving clonogens and the
expected number of cells (λ) is equal to Ns.Thus equation (2.6) becomes
TCP = P (k = 0) =
N0s e
−Ns
0!
= e−Ns (2.7)
2.1.2 Inter-patient radiosensitivity variation
As mentioned earlier the clinically observed DRCs (from analyzing patient treatment
outcomes treated with different prescription doses) are shallower than observed by in
vitro experiments. Numerous dose-response curves have been published in the litera-
ture [72–78]. None of these curves exhibit steepness such as that observed in invitro
experiments. Many hypotheses have been proposed in the literature for the shallow-
ness of the clinically observed DRCs [79,80]. But the most credible is the inter-patient
radiosensitivity of the tumor cells [79, 81–83]. The application of the TCP formalism
in (2.7) produces a steep dose-response curve rather than a relatively shallow one. To
account for the variation in the inter-patient radiosensitivity, equation (2.7) has been
modified such that the TCP is calculated by averaging over a population of patients
with “normally” distributed α with a standard deviation of σα. The TCP formalism ac-
counting for inter-patient radiosensitivity is shown in equation 2.8. The dose-response
curves generated for different σα is shown in figure 2.2. The distinct steepness for
σα = 0 can be noted, while other curves exhibit a relatively shallow dose-response
curve. The slope of the dose-response curve decreases with increasing σα.
TCP =
1
σα
√
2pi
∫ ∞
0
(
∏
i
exp(−Ns)exp[−(α− α¯)2)/2σα2]dα (2.8)
where σα is the standard deviation of radiosensitivity α¯ in a population of patients.
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Figure 2.2: Dose-response curves for different σα. Other parameters used for the cal-
culations are; α¯ = 0.3Gy−1, ρcl = 1.0E7 cc−1, α/β=10Gy and number of treatment
fractions=20
.
2.1.3 Random sampling of α over Gaussian distribution
Accounting for inter-patient radiosensitivity can be done mathematically using equation
(2.8); which uses a uniform sampling technique for the integration. However, it can also
be randomly sampled over a Gaussian distribution of α; which is known as Monte Carlo
integration. A comparison of both the methods is given in this section. TCP inclusive of
inter-patient radiosensitivity using Monte Carlo integration is given by equation (2.9).
TCP =
1
n
n∑
1
TCP (αn) (2.9)
where αn is the α value at n
th iteration randomly sampled from the Gaussian
distribution of α characterized by σα. TCP (αn) is calculated according to equation
(2.7) by substituting α with αn.
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In a “normal” distribution of α, the range varies from −∞ to +∞. However in real-
ity, none of the patients would have a extremely low, high or negative radiosensitivity.
Thus, the values are truncated on both sides of the Gaussian distribution around α¯
with a interval of α¯± 2σα. The sampled α values falling outside the α¯± 2σα range are
neglected in the Monte Carlo integration.
Figure 2.3: Clipped-Gaussian distribution of α. Only values in the white region of the
bell curve are used in the calculations.
The TCP values calculated using both methods for different α¯ values at different
dose levels (50, 60, 70 Gy) for three different σα values are shown in figure 2.4. Moreover,
DRC produced with two integration methods are shown in figure 2.5 for σα of 0.07Gy
−1.
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Figure 2.4: Random sampling vs Integrating over the Gaussian distribution of α. The
hatched bars represent TCP values calculated by random sampling and the solid bars
represent values calculated by averaging over the Gaussian α. TCP parameters are
ρcl = 1.0E7 cc
−1 and α/β = 10 .
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Figure 2.5: Dose-response curve generated by integration and random sampling meth-
ods of accounting for inter-patient radiosensitivity variation. The TCP parameters used
in the calculations are α¯ = 0.30Gy−1, α/β = 10Gy, σα = 0.07Gy−1, ρcl = 1.0E7 cc−1.
2.1.4 TCP calculation by dose summation and SF methods
TCP values inclusive of geometric uncertainties are calculated by summing the dose
values for each fraction according to the displacement of the voxels. Since every voxel
receives a different dose at each fraction, the biological effect of assuming that every
voxel receives a uniform dose of Dmean(i.e.,Dtotal/n) every fraction is not radiobiolog-
ically accurate. However, it has been shown by Bortfeld et al that for fractionated
treatments where the voxel doses vary moderately between fractions, the radiobiolog-
ical effects resulting from dose summation or calculating the TCP by calculating the
surviving-fraction (SF) each fraction are equivalent [84]. This consideration applies
especially to tumor, which have higher α/β ratio than normal tissues which means that
tumors are less sensitive to fraction size.Moreover, tumors experience relatively less
dose variation due to displacements than OARs since tumors are surrounded by a rel-
atively high dose region compared to OARs. This is demonstrated in figure 2.8, where
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TCP values are calculated from the final summed dose values in each voxel and by
calculating the SF in each voxel at every fraction. TCP calculation by the SF method
is shown in figure 2.6. At the end of each fraction the number of surviving cells in each
voxel is calculated and the total remaining cells in all voxels are summed to obtain
the remaining number of cells in the tumor volume. Considerable difference can be
found only at low TCP values (where the underdosing due to tumour displacements is
high, leading to lesser TCP compared to the static tumour) between the two methods
for both 20 and 3 fractions. Some studies have shown that the α/β ratio for prostate
tumours can be as low as 3 Gy [85–88]. Hence, the effect of α/β is briefly studied
for different standard deviations of systematic and random errors for high (10) and
low (3.0) α/β ratios with a PTV margin of 6 mm. The description of the simulation
process is shown in chapters 3 & 4. Other simulation parameters used are similar to
the one used in margin determination study. The σα used is 0.114 Gy
−1. The results
are given in table 2.1. To achieve the same TCP as with α/β of 10 Gy the α parameter
is adjusted to acheive 50% TCP in the α/β of 3 Gy−1. Thus is due to the fact that
TCP parameters should always be fitted to the clinically observed treatment outcomes.
The α/β parameter is found to have little impact on the TCP loss than σα since the
relative drop in TCP is determined by the steepness of the dose-response curve which
is determined by σα. The maximum deviation found between two α/β is 1.2%.
Table 2.1: TCP loss vs α/β ratios
Σ, σ 10Gy(α = 0.3Gy−1) 3 Gy(α = 0.2Gy−1)
1,1 50.0 50.0
2,2 50.0 49.2
3,3 41.83 41.3
4,4 27.30 26.10
5,5 14.81 15.26
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Figure 2.6: TCP calculation by SF method. N1,N2...Nn represent the initial number
of clonogenic cells in each individual voxel n, whereas f1,f2... represent the fraction
number. The number of surviving cells in each voxel is calculated at the end of each
fraction and the total cells in each voxel are summed at the end of treatment to obtain
the total number of remaining cells in the whole tumour.
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Figure 2.7: Total number of surviving cells at each fraction for different Σ and σ
(Σ,σ=3,4, and 5 mm) compared with the static case. TCP parameters used for the
calculations are; α¯ = 0.3Gy−1, ρcl = 1.0E7 cc−1, α/β=10Gy and number of treatment
fractions=20.
The decrease in the total number of cells at each fraction is shown in semi-log plot
in figure 2.7 for a 20 fraction treatment with different standard deviations of systematic
and random errors. Figure 2.8 shows TCP calculated for 9 different simulations using
SF and dose summation methods with systematic and random errors randomly drawn
from their Gaussian distributions. Σ,σ=3 and the TCP parameters are same as used
in generating plots in figure 2.7.
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Figure 2.8: Comparison of TCP calculation by dose summation and SF methods for
nine different simulations.
2.1.5 Mean population TCP calculation
Most of the results in this thesis are evaluated on the basis of population mean TCP
(TCP pop), which provides the mean of the TCPpop(inclusive of inter-patient radiosen-
sitivity variation) values calculated from a large number of TCP values generated from
the simulations for each plan. The population mean TCP is calculated as shown in
equation 6.23.
TCP pop =
1
n
n∑
1
TCP pop (2.10)
where n is the number of simulations.
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Chapter 3
Biosim: A software program for
simulating geometric
uncertainties and interplay effect
3.1 Introduction
Biosim is an in-house developed modular software written in C++ for the purpose of
simulating the radiobiological effect of geometric uncertainties, variation of clonogen
density in the tumour and the interplay effect in step-and-shoot IMRT treatments. In
the current version, it supports the Millennium120 multi-leaf collimator (MLC) (Varian
Medical Systems, Palo Alto, CA) for simulating interplay effect and visualizing the
beam’s eye view (BEV), but it can be easily extended to other MLCs. Visualization Tool
Kit (VTK) is used for image processing and 3D visualization and the open source edition
of Qt is used for developing the graphical user interface [89]. Biosim can read DICOM
CT images, RT structure sets, RT Dose and RT plans using the GDCM DICOM toolkit
[90]. Moreover, a cubical phantom with a user-specified uniform Hounsfield unit (HU)
can be generated along with other standard shapes such as spheres, cylinders and cubes
with user specified dimensions as volumes-of-interest (VOI). Dose-volume histograms
(DVH) can be independently calculated for the VOIs. Dose can be either imported
from TPS in DICOM format or a spherical dose distribution can be generated with
a Gaussian penumbra. However, for studying the interplay effect a ray-tracing based
dose model is used. The “Enhanced Marsden” model is used to calculate TCP to take
account of geometrical uncertainties and interplay effect.
3.2 VTK
VTK is an open-source object-oriented c++ class library for 3D computer graphics ,
visualization and image processing [91]. It offers a variety of algorithms to visualize
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scalars, vectors, tensors and volume rendering of 3D medical datasets such as CT
and MRI. It also offers many modelling techniques such as mesh generation, mesh
smoothing, polygon reduction, cutting, clipping and triangulation to mention a few of
them.
3.2.1 Rendering in VTK
VTK uses a pipeline architecture connecting multiple elements such as data sources,
filters, mappers and renderer to render the data into the render window. A typical
VTK rendering pipeline is shown in figure 3.1. Filters operate on the source data and
produce an output different from the source data then the modified output is processed
through the mapper which converts the data into graphics primitives (actors) to be
rendered into the render window by the renderer.
Figure 3.1: Typical rendering pipeline in VTK
3.2.2 VTK Image Data
Imported DICOM CT images and manually created phantom images are represented
internally as vtkImageData(a special vtk class) with attributes such as spacing, origin,
dimension and data type in Biosim. The vtk coordinate system with the image data
is shown in figure 3.2. vtkImageData is a 3D matrix of uniform spacing along the
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individual axes, but can be different on each axis. The first voxel of the vtkImageData
is at the lower left corner of the image; with k increasing into the screen. If the index
(i,j,k) of the specific voxel in image coordinates is known then its world coordinates
(x,y,z) can be calculated using the information in the vtkImageData class as shown in
equation (3.1)-(3.3).
x = Ox + i ∗ Sx (3.1)
y = Oy + j ∗ Sy (3.2)
z = Oz + k ∗ Sz (3.3)
where O(x,y,z) is the origin and S(x,y,z) is the spacing of the image data in their
corresponding axis.
Figure 3.2: VTK world (x-y-z) and image (i-j-k) coordinate system with vtkImageData
3.3 Importing DICOM datasets
As mentioned earlier, Biosim can import CT, RTDOSE, RTSTRUCT and RTPLAN
and cumulative DVHs in DICOM format. A c++ class named as “DCMImporter” has
been developed for this purpose. Some of the relevant DICOM tags used for processing
the DICOM data are given in table 3.1.
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Table 3.1: DICOM Tags used for processing RT dataset
Modality Tag Name Tag Value
RTPLAN Dose reference sequence 0x300a,0x0010
RTPLAN Fraction group sequence 0x300a,0x0070
RTPLAN Beam control sequence 0x300a,0x00b0
RTPLAN Beam limiting device sequence 0x300a,0x011a
RTPLAN Control point sequence 0x300a,0x0111
RTPLAN Plan label 0x300a,0x0002
RTPLAN Fractions planned 0x300a,0x0078
RTPLAN Machine name 0x300a,0x00b2
RTPLAN Beam Name 0x300a,0x00c2
RTPLAN Beam type 0x300a,0x00c4
RTPLAN Beam Energy 0x300a,0x0114
RTPLAN Beam Angle 0x300a,0x011e
RTPLAN Collimator Angle 0x300a,0x0120
RTPLAN Couch Angle 0x300a,0x0122
RTPLAN SSD 0x300a,0x0130
RTPLAN FieldSize, MLC leaf positions 0x300a,0x011c
RTPLAN Isocentre 0x300a,0x012c
RTPLAN Meter set (MU) 0x300a,0x0086
RTPLAN Beam Dose 0x300a,0x0084
RTDOSE Dose gride scaling factor 0x3004,0x000e
RTDVH DVH sequence 0x3004,0x0050
RTDVH DVH type 0x3004,0x0001
RTDVH Referenced ROI no. 0x3006,0x0084
RTDVH DVH bins 0x3004,0x0056
RTSTRUCT ROI sequence 0x3006,0x0020
RTSTRUCT ROI contour sequence 0x3006,0x0039
RTSTRUCT Struct set label 0x3006,0x0002
RTSTRUCT ROI No. 0x3006,0x0084
RTSTRUCT ROI color 0x3006,0x002a
RTSTRUCT ROI name 0x3006,0x0026
RTSTRUCT ROI type 0x3006,0x00a4
RTSTRUCT Contour data 0x3006,0x0050
RTSTRUCT Contour slice data 0x3006,0x0050
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3.4 Graphical User Interface
Biosim provides four sub windows in a multiple document interface area for viewing
axial, sagittal, coronal and 3D views of the ROIs, beams and dose. The axial, sagittal
and coronal windows contain a vertical slider to slice through the dataset in their
corresponding axis. BEV can also be viewed for co-planar gantry angles. The details of
the imported plans are shown in a resizable table format. The details of the imported
structures and some general information are provided in a structured tree format.
Figure 3.3: GUI with axial, sagittal, coronal and 3D views
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Figure 3.4: BEV for 0o gantry angle with bladder, rectum and prostate shown in blue,
yellow and red respectively.
Figure 3.5: BEV for 90o gantry angle with bladder, rectum and prostate shown in blue,
yellow and red respectively.
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3.5 Mesh generation
Figure 3.6 shows the steps involved in generating a 3D surface mesh using the Marching
Cubes algorithm in VTK. Some of the generated meshes can be seen in figures 3.4 and
3.5 in the BEV.
Figure 3.6: General steps in generating a mesh in VTK
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3.6 Anisotropic margin growing algorithm
Structures can be anisotropically expanded or contracted in Biosim with user-specified
margin in each axis. The general steps involved in margin growing are shown in figure
3.9. Structure contraction can be achieved with the same methodology as shown in
figure 3.9,except by inverting the binary image of the triangular mesh (with “0” inside
and “1” outside).
Figure 3.7: CTV (red) margin expanded 10mm isotropically (yellow)
Figure 3.8: Spinal cord (cyan) expanded 5mm istropically (yellow)
36
Figure 3.9: Steps involved in anisotropic margin expansion
3.7 DVH Calculation
DVHs are calculated using some of the classes in VTK with some additional functions
in Biosim. In radiotherapy planning, the 3D shape of the structures is generally de-
rived from a set of 2D contours drawn on the axial CT images. A surface mesh of
the structure is generated from the set of 2D contours using vtkMarchingCubes for
the structure-of-interest, and the resulting mesh is stored as a vtkPolyData. The dose
calculated within the patient volume by the TPS is a 3D array with a commonly-used
resolution of 2-to-3 mm. This 3D dose array is generally a matrix of uniform spacing
in all three axes, which can be imported into Biosim as vtkImageData. The key step
in calculating the DVH is to identify the voxels inside the structure-of-interest. This
can be achieved with a combination of some of the VTK classes, namely vtkPolyData-
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ToImageStencil and vtkImageStencil. The dose outside the structure is set to zero using
SetBackgroundValue in vtkImageStencil. Then, the voxels inside the structure can be
easily identified by iterating over the binary image matrix. The entire dose array and
dose extracted for bladder using vtkPolyDataToImageStencil is shown on an axial slice
in figures 3.10 and 3.11 respectively.
Figure 3.12 shows the steps involved in calculating differential DVH in VTK. A
representative differential DVH calculated for tumour is shown in figure 3.12.
Figure 3.10: Dose grid with bladder contour
Figure 3.11: Dose extracted with bladder contour
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Figure 3.12: General steps in calculating a differential DVH in VTK
Figure 3.13: Differential DVH for a tumour calculated in Biosim
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The DVHs calculated using EclipseTM(Varian Medical Systems,Palo,Alto) and Biosim
are shown in figure 3.14 and 3.15 for a prostate and breast case respectively.
Figure 3.14: Cumulative DVHs calculated in Biosim compared with EclipseTM DVHs
for prostate case
Figure 3.15: Cumulative DVHs calculated in Biosim compared with EclipseTM DVHs
for breast case
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3.7.1 Volume calculation in Biosim
The volume for the given structure is calculated as the number of voxels times the voxel
volume. The volume calculated using VTK and analytical methods for a sphere (25 mm
radius), cube (25 mm sides), and cylinder (25 mm radius and 40 mm length) are shown
for 1 mm and 2.5 mm resolution of dose matrices in figure 3.16. The results are closer
to the analytical method for 1mm resolution because of the reduced partial-volume
effect.
Figure 3.16: Volume calculation compared with analytical methods
3.8 Spherical dose distribution
A spherical dose distribution with a Gaussian penumbra can be generated with a user
specified standard deviation as shown in figure 3.17. To generate such a distribution;
the selected structure of interest (PTV) is expanded 5mm (where the 50% isodose
surface will be placed) and ‘flood filled’ with a uniform value. This binary image is
then convolved with a 3D Gaussian kernel to obtain the dose distribution. It is also
possible to generate dose distributions with different penumbra widths along different
axes, but a uniform penumbra width (same σ) is used through out the work carried out
in this thesis using spherical dose distributions. A σ of 3.2 mm is used which results in
5mm between the 95% and 50% isodose surfaces.
41
Figure 3.17: Gaussian convolution kernel parameters dialog with standard deviations
set in each axis (3.2 mm)
(a) Dose colour wash on central axial slice
(b) Dose profile across PTV (white line shown in
figure a). The ∼ 95% covers the PTV whereas
the CTV receives 100% dose
Figure 3.18: Dose color wash and the dose profile across the PTV
42
3.9 Four-field brick dose distribution
To simulate a conventional four-field brick plan, a 3D matrix is filled with uniform
value, in the shape determined by the jaw aperture. The beam divergence is calculated
by assuming a source-to-axis distance (SAD) of 100 cm. This matrix is convolved plane-
by-plane from top to bottom by a Gaussian kernel (σ=0.8 mm) to achieve a penumbra
width of ∼6 mm at the isocentre level. A Collimator leakage of 0.5% is assumed outside
the field. The resulting dose distribution and the percentage depth dose curve for the
anterior field is shown in figure 3.20a and 3.20b respectively. The 2D Gaussian kernel
is shown in figure 3.19. Tissue-maximum ratio (TMR) values for a 6MV beam taken
from BJR supplement 25 [92] for the respective field size are used to calculate the dose
in each voxel. Three more dose matrices are generated by applying matrix rotations
of 90,180 and 270 degrees about the isocentre. The dose distribution for a four-field
box is generated by summing all four matrices and normalized at the isocentre. The
resulting dose distribution for 5x5 cm2 anterior field is shown in figure 6.12. The cross
profile at the isocentre level is shown in figure 3.21.
Figure 3.19: 2D Gaussian kernel
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(a) Dose color wash for the anterior 5x5 cm2
field (b) Depth dose profile
Figure 3.20: Dose color wash and its corresponding depth dose profile for the anterior
field
Figure 3.21: Cross profile for the anterior 5x5 cm2 field with the penumbra width shown
The summed dose distribution for the 4F-brick technique by applying matrix rota-
tions and its lateral cross profile are shown in figures 6.12 and 3.22b respectively and
their isodose lines are shown in figure 3.23.
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(a) Dose color wash (b) Lateral cross-profile
Figure 3.22: Dose color wash and lateral cross profile for 4F-brick technique with 5x5
cm2 fields
Figure 3.23: Isodose lines for the 4F-brick technique in axial, sagittal and coronal planes
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3.10 Simulation of geometric uncertainties in Biosim
Systematic(Σ) and random(σ) uncertainties can be simulated for VOIs generated ei-
ther from DICOM objects or standard shapes. The systematic and random standard
deviations and the TCP parameters can be set using the simulation dialog as shown in
figure 3.24. The dose grid is first resampled to 1x1x1 mm3 using cubic interpolation
since the displacement resolution is 1 mm. The target structure of interest (generally
CTV) is divided into 1x1x1 mm3 voxels. The voxel indices in the corresponding dose
grid are found using equations (3.1)-(3.3). Systematic and random errors are randomly
generated using a quasi-random number generator from the Gaussian distribution of
their corresponding errors (characterized by their standard deviations). A 3xn array
[(x,y,z),n] of both errors were generated for each treatment, where n is the number of
fractions. The values for the systematic error are the same for all the fractions in a
particular treatment, but different from fraction-to-fraction in the random error array.
The error vector in each element of the array is summed and rounded off to the nearest
integer to provide the resulting displacement for each fraction.
Figure 3.24: Simulation dialog with TCP parameters, systematic(Σ) and random(σ)
error standard deviations set. The maximum number of runs and the desired standard
error of mean (SEM) for the simulations can be set. Simulation automatically stops
when either of the criteria is met.
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Figure 3.25: Summation of error vectors
Figure 3.26: Depiction of dose accumulation process
Consider the blue voxel in figure 3.26 as the voxel-of-interest for which the dose
needs to be accumulated. The green voxels are the position of blue voxel in each fraction
(f1,f2....f6) due to geometric uncertainties. Then the cumulative dose to blue voxel is
the summation of dose values at voxels f1 to f6. This is mathematically expressed in
equation (3.4).
Dvoxel =
f=n∑
f=0
Df (3.4)
Where Df is the dose at the position of the voxel in fraction f . Differential DVHs
are calculated from the accumulated doses to compute TCP values. The simulations
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are repeated several times until the standard error of the mean TCP is ≤ 0.15%. The
simulation process in shown in figure 3.27 and the resulting sample DVHs are shown
in figure 3.28 respectively .
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Figure 3.27: Geometric uncertainties simulation process: One systematic error per
treatment and one random error per each fraction in the treatment are generated using
a quasi-random number generator. Subsequently, the dose in each voxel inside the CTV
is summed using the error vector resulting for each fraction to obtain the cumulative
dose at the end of the treatment. Differential DVHs are generated to calculate TCP.
The entire process is repeated several times (n number of items) until the standard
error of the mean TCP values obtained is ≤ 0.15.
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Figure 3.28: Representative DVHs inclusive of geometric uncertainties for a 25 mm ra-
dial CTV. The DVH for the static CTV is shown with the red marker. The PTV margin
is 8mm with Σ, σ=3mm.The dose was 55Gy in 20 fractions with α¯ = 0.301Gy−1, σα =
0.114Gy−1, α/β = 10Gy, ρcl = 1.0E7 cells/cc. Take note of the dose range.
3.11 Varying clonogen density in GTV-CTV region
A clonogen density grid with an exponential fall-off can be generated in Biosim. This
is achieved by calculating the distance from the nearest surface of the surface mesh
(GTV) to every voxel that lies outside the specified surface. Using the distance value
the clonogen density can be calculated with a user specified slope (s). The maximum
distance up to which the calculation is performed can also be set, which is usually up
to the CTV. The clonogen density input dialog is shown in figure 3.29 with a clonogen
density profile is shown along with the dose profile in figure 3.30 for a 20 mm radial
GTV and 25 mm radial CTV with a slope factor of ‘3’. The density values are truncated
at the edge of the CTV, i.e., the density values only inside the GTV-CTV space are
considered for the calculations.
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Figure 3.29: Exponential clonogen input dialog
Figure 3.30: Profile of clonogen density (dashed) and dose (solid) across GTV, CTV
and PTV.
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Chapter 4
Loss of local control due to
tumour displacement as a
function of margin
size,dose-response slope and
number of fractions
4.1 Introduction
External beam radiotherapy comprises several procedures from imaging through treat-
ment delivery, involving patient positioning, imaging, target delineation, dose calcula-
tion and treatment delivery. Uncertainties are inherent in all of the above procedures
which can be reduced but not eliminated by quality assurance and quality control pro-
cedures. These uncertainties are categorized as systematic and random errors [93, 94].
Systematic (preparation) errors are those which propagate throughout the course of
treatment with the same magnitude and direction. Random (execution) errors can
vary from fraction to fraction, examples include organ motion or day-to-day setup vari-
ations, resulting in dose not being delivered as intended. Assuming shift-invariance
(ignoring the effects of changes in source-to-surface distance (SSD), change in depth,
surrounding tissue density on dose delivered) systematic errors tend to shift the dose
distribution while random errors blur the dose distribution [53,94,95]. To compensate
for these uncertainties a planning target volume (PTV) is created by expanding the
clinical target volume (CTV) by an appropriate margin [?, ?]. Adequate margin size
is crucial to obtain good coverage of the target volume during treatment delivery but
the unavoidable inclusion of normal tissues in this margin usually limits the dose that
can be delivered due to the risk of complications. In reality, systematic and random
errors may, in addition to translations, include rotation and deformation of target as
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well. These rotational and deformation uncertainties will, however, not considered in
this study in order to limit its complexity.
Probability density functions (PDFs) of systematic and random errors in radiother-
apy delivery have been modelled as Gaussian distributions with empirically determined
standard deviations. This makes it possible, as often suggested in the literature, to
model the effect of random errors by convolving the dose distribution with the random
error PDF [96–99].The convolution method has been shown to overestimate the radio-
biological indices for the target volumes and underestimate for the organs-at-risk [100].
Also, the radiobiological dose-response relationship is non-linear and the linear convolu-
tion of dose does not reflect the biological effects on the individual voxels correctly [84].
It is nevertheless accurate enough for moderately fractionated radiotherapy (number
of fractions >15) and small changes in the dose experienced by the tumour [98,101].
For given standard deviations of systematic (Σ) and random errors (σ), several
authors have proposed margin recipes meeting various criteria based on the minimum
delivery of a certain percentage of the prescription dose to the CTV for a certain
percentage of patients [51, 94, 101]. For example, vanHerket al proposed a margin of
2.5Σ + 0.7σ whereas Stroom et al proposed a margin of 2.0Σ + 0.7σ [51]. While both
recipes have the same coefficient for random errors, the coefficient for systematic errors
differs slightly due to the criteria chosen to derive the margins. It is obvious from the
margin recipe formulas that the systematic errors are more detrimental than random
errors, which has much larger coefficients. The effect of individual errors (Σ, σ) and
both combined is shown in figure 4.1, which clearly shown that systematic errors alone
or combined with random errors is more detrimental than random errors alone.
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Figure 4.1: Cumulative DVHs with systematic and random errors individually (ran-
dom alone, systematic alone) and combined (systematic+random) for a 20 fraction
treatment. The DVH for the static case is shown with markers.
These and similar margin recipes consider criteria which are based on physical dose
to the tumour. Such criterion are not directly clinically relevant. A more clinically rele-
vant criterion is the tumour control probability (TCP), a metric which has already been
considered for margin determination. For example, with the criterion of ≤ 1% TCP
loss to prostate tumours, van Herk et al proposed a modified margin recipe, 2.5Σ+0.7σ
-3mm [52], thus subtracting a constant from their previously published margin recipe.
This strongly suggests that physical dose-based margin recipes are conservative and re-
duced margins can be used from the radiobiological point-of-view. To generalize their
results to treatments with a small number of fractions, Van Herket al proposed another
revision to their recipe by adding an uncertainty term to the systematic error, which
is standard deviation of the random error divided by the square root of the number of
fractions [94]. Hypofractionated treatments such as SABR are more widely used for
lung tumours [102,103]. The margins required for these hypofractionated treatments is
indeed becoming increasingly important. Moreover, if the criteria for margin determi-
nation are based on TCP, it is important to consider variation in TCP parameters and
their impact on derived margins. In particular it is known that different tumours have
different dose-response slopes (γ50) and their differences may influence the magnitude
of derived margins.
In this work we study the combined effects of dose conformity, fraction number, γ50
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as well as Σ and σ on margins using the criteria of ≤ 1% loss in the population mean
TCP (TCP ) and of ≤ 1% loss in 90% of the patients, each loss being relative to the
TCP obtained for a static tumour.
4.2 Material and Methods
4.2.1 TCP calculation for different γ50
TCP for each treatment (or patient) and mean population TCP (TCP ) for n patients
are calculated using the enhanced Marsden model [71] as shown in chapter 2. Since
γ50 is not a parameter in this TCP model, it is impossible to directly use the published
values. So σα was fitted to produce the same gradient at TCP=50% as the slopes in the
literature, for α¯ fixed at 0.30 Gy−1. The γ50 values for squamous cell carcinoma (SCC)
is shown to be in the range 1.5 to 2.5 [68]. So their corresponding values of σalpha in
that range representing different tumour types with shallow, steep and intermediate
dose-response characteristics were chosen namely 0.8, 1.8, 2.8 and 3.9. The σα value
for NSCLC was taken from Nahum et al [104] and the corresponding γ50 is shown table
5.1.
Table 4.1: γ50 and their corresponding σα for different tumour types
Tumour Type γ50 σα
SCC 0.8 0.218
SCC 1.8 0.070
SCC 2.8 0.048
NSCLC 3.9 0.037
The TCP parameters used in the calculations for different σα are α¯ =0.30 Gy
−1,
ρcl=10
7cc−1 and α/β=10.0.
4.2.2 Dose models
Firstly, a spherical dose distribution with a Gaussian penumbra and a 4F box-technique
to respectively mimic fully and less conformal dose distributions were used to simulate
the effect of geometric uncertainties with a fixed standard deviation (3 mm for both
Σ and σ) for four different γ50 (covering the range of observed slopes, taken from
the literature) for 3, 5, 10, 20 and 30 fractions. Secondly, different combinations of
systematic and random uncertainties (Σ ,σ) namely (1, 1), (1, 3), (3, 1), (3, 3) were
used to derive the margins required for a ≤ 1% loss in TCP for the range of number of
fractions and γ50 mentioned above. A Monte Carlo approach was used to simulate the
effect of geometric uncertainties on TCP. The dose models are generated as described
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in sections 3.8 and 3.9 in chapter 3 (Biosim). In the spherical dose distribution the
95% isodose surface just encompasses the PTV and the distance between the 95% and
50% isodoses is approximately 5mm. This level of dose conformity cannot be realized in
practice, but represents a best-case in terms of conformity and will be the most sensitive
to tumour motion, due to the equal and rapid dose fall off in all directions. For the 4F
box-technique technique the 95% isodose surface encompasses the PTV but there is a
considerable amount of incidental dose outside the PTV. This dose distribution is used
to study the effect of less conformal technique and the incidental dose outside PTV on
the required PTV margins.
4.2.3 Monte Carlo simulation of geometric uncertainties
To simulate the geometric uncertainties, systematic and random displacement vectors
were sampled from two Gaussian distributions using pseudo-random number genera-
tor. Different sets of standard deviations were chosen for both systematic and random
displacement distributions. One systematic displacement per treatment (patient) and
one random displacement for each fraction of each treatment were sampled. The vector
sum of systematic and random vectors give the total displacement for each fraction
of the treatment. This method of explicitly simulating the random errors was chosen
over the convolution/blurring method, because the later is valid only when using a
large number of fractions. A grid resolution of 1x1x1 mm3 was used for the calcula-
tions. Doses were summed for each voxel over the entire treatment and dose-volume
histograms for each patient computed. Even though this method of summing the doses
linearly at each fraction is not strictly correct but the radiobiological differences between
this approach and that of applying the linear quadratic (LQ) model at each fraction
are clinically insignificant [105]. The number of simulated treatments, n was increased
until the standard error of the mean calculated as SEMTCP = (SDTCP /n ) was ≤ 0.15.
Where SD is the sample standard deviation. The number of simulations ranged
from a few hundred to a few thousand depending on the PTV margin.
The PTV margin was varied from 3 mm to 12 mm in steps of 1mm and the simu-
lations were performed on both dose distributions for different dose-response slope and
for 3, 5, 10, 20 and 30 fractions. The prescription dose for 20 fractions was 55 Gy
as per the local protocol for lung radiotherapy and prescribed doses for other fraction
numbers were derived such that they all resulted in 50% TCP for a static tumor. We
chose 50% as our reference TCP value to be at the steepest point in the dose-response
curve. It is therefore at this point that TCP will undergo the largest changes caused
by any dose degradation due to geometric uncertainties. The margins required at this
TCP level can thus be safely applied for any other TCP value. The TCP and percent-
age of patients receiving ≤ 1% TCP loss from the static tumour TCP were calculated
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for each case. Clonogen proliferation was not considered in this study.
Figure 6.17 shows the typical variation in dose and TCP (for respective DVH shown)
for a CTV of 25 mm radius for 3 and 30 fractions with a PTV margin of 8 mm for
Σ, σ = 4 mm (deliberately a smaller margin was chosen to show the differences clearly)
. The prescription dose was chosen to provide 50% TCP for a static tumour. TCP
values vary more for 3 fractions compared to 30 fractions, as would be expected.
Figure 4.2: Differential DVHs showing the effect of fractionation on cumulative dose
to CTV. TCP for the selected DVHs is shown with Σ = σ = 4 mm, as is the mean
population TCP (averaged over a large number of DVHs as described in the text). The
individual TCP values are shown in the figure legend.
4.3 Results
4.3.1 TCP vs Margin size
TCP and ≤1% in 90% of the patients for different number of fractions and dose-
response slope values are shown in figure 4.3 for spherical and four-field box dose
distributions for 3 mm Σ and σ. From these figures gradually increases and attains a
constant value (highest achievable for the given dose) above a certain margin. They
also show clearly that the margins required for smaller numbers of fractions are larger
than those for greater numbers of fractions, indicating hypofractionated treatments are
more vulnerable to geometric uncertainties. Furthermore, the difference between the
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margins required for ≤ 1% loss for 3 and 30 fractions increases as γ50 increases. The
margin for the four-field box distribution shows a similar dependence on fractionation
and γ50 but the margins required are reduced. This is due to a reduced dose fall-off from
opposing beams. Similar trends can be seen for the percentage of patients receiving
≤ % loss in TCP (figure 4.4 a & b). But the required margins are slightly larger than
the later case.
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Figure 4.3: TCP plotted against PTV margin for different number of fractions for
spherical and four-field box dose distributions with Σ &σ = 3mm for different γ50.
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Figure 4.4: Percentage of patients with ≤ 1% loss in TCP vs PTV margin for a)
spherical and b) four-field box dose distributions with Σ &σ =3mm for different γ50.
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4.3.2 Margin comparison with published recipes
The differences between fractionation-dependent margins calculated using van Herk
et al TCP-based recipe [53] and the TCP- loss based margins derived in this work
for Σ=1 and σ =3 mm are shown in figure 4.5. The fractionation is accounted in
the TCP-based recipe as suggested by van Herk et al [52] by quadratically adding an
additional term to Σ (which is calculated by dividing σ by the square root of the number
of fractions). Figure 4.5 clearly demonstrates that fractionation-dependent margins
considerably increase as the number of fractions decreases for both the margins derived
using van Herk et al TCP-based recipe and from this work. For a fixed value of γ50, both
curves are still essentially parallel, showing that van Herks correction term reproduces
the fractionation dependence found in this work. It should be born in mind that the
van Herk TCP-based recipe is derived for prostate tumours which have a shallow DRC
(low γ50) and for large number of fractions. The margins calculated in this work and
van Herk et al [52] TCP-based recipe is almost the same for a large number of fractions
and low γ50 . However, the margins differ considerably for other fractions and γ50 . The
differences could be greater for larger Σ and σ. The gap between the two surfaces widens
as γ50 increases, which demonstrates the importance of considering dose-response slope
of tumours when deriving margins. This also emphasizes the fact that margins derived
from a TCP-based recipe assuming a particular γ50 will not apply for tumours with
different γ50.
61
Figure 4.5: Surface plot of margin required for ≤ 1% loss in TCP pop as a function
of treatment fractions and γ50 for different combinations of systematic and random
uncertainties with their corresponding physical dose-based margins shown as a plane
(Red dots represent actual data values).
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4.3.3 Fractionation corrected vs uncorrected Margins
The differences between fractionation-corrected and uncorrected margins calculated ac-
cording to the physical dose-based recipe [94] with the TCP loss based margins forΣ=1
and σ =3 mm are shown in figure 4.6. The fractionation is accounted for by quadrati-
cally adding an uncertainty term to Σ, which is calculated by dividing σ by the square
root of the number of fractions. Fractionation corrected margins significantly increase
as the number of fractions decrease. Nevertheless, TCP-based margins accounting for
fractionation are significantly smaller than fractionation-corrected margins calculated
using a physical dose-based recipe.
Figure 4.6: Van Herk et al (VH) margin plane corrected for fractionation and uncor-
rected with the margins obtained in this study for ≤ 1% loss in TCP
4.3.4 Dependence of margins on dose conformity
To demonstrate the dependence of margins on dose conformity; a prostate tumour with
different PTV margins was planned with different techniques. The techniques include
three-field (Anterior, 2 laterals), four-field (AP-PA , 2 laterals), IMRT (5 fields) and
spherical dose-distribution with Gaussian penumbra. The field arrangements are shown
in figure 4.7. The spherical dose distribution is an artificial dose distribution which has
no beam entry or exit paths and has the least incidental dose among all four techniques.
The PTV margin was varied from 2mm to 10mm in steps of 1mm. The MLC leaves
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were refitted in the planning system and the dose recalculated for three-field and four-
filed techniques. For the IMRT technique the plans were reoptimized considering the
newly generated PTV volumes. For the spherically-symmetric dose distribution the
dose was regenerated for the new PTV volumes. DICOM datasets(CT, RT dose, RT
structures) were imported into Biosim for each PTV margin and technique. CTV
displacements were simulated assuming 3mm standard deviation for both systematic
and random errors for a 20 fraction treatment. The prescription dose was adjusted for
each technique to obtain 50% TCP for the static case.
Figure 4.7: Margin vs technique. Wedges were used for the 3-field plan but wedge
display is not currently supported in Biosim.
The Margin-TCP curves asymptotically increases for all the techniques.The margins
required for the l ≤ 1% loss in TCP increases as the dose conformity increases, which
in this case increases in the order; spherically-symmetric distribution, IMRT, four-field
and three-field distributions. From figure 4.7 it’s also evident that the rate of TCP
drop significantly increases with increasing dose conformity.
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Figure 4.8: Margin required for ≤ 1% loss in TCP vs technique. Σ, σ = 3mm
4.3.5 Dependence of TCP loss on tumour volume
To study the effect of TCP loss on tumour volume, CTV radius was varied from 15 to
45 mm in steps of 5mm. Prescription doses were adjusted to achieve 50% TCP in 20
fractions for the static tumour. A margin of 6mm is used. This is from our analysis
of previous results which results in ≤ 1% loss in TCP for a 25 mm radial tumour
for the number of fractions (20) and γ50(1.8) used. TCP losses were obtained by
running the simulations until the standard error is ≤0.2 with 3mm standard deviations
of systematic and random uncertainties. The TCP parameters used were same as used
in other calculations in this study except γ50 was 1.8 (average dose-response slope).
The variation of TCP loss with tumour volume is shown in figure 4.9.
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Figure 4.9: Variation of TCP loss with CTV volume with standard error ( α¯=0.30
Gy−1, σα= 0.07 Gy−1, ρcl=107cm−3 and α/β =10 Gy)
4.4 Discussion
TCP-based margin recipe for prostate tumours treated with three fields has been re-
ported and the margins were shown to be much smaller than the physical dose-based
recipes (van Herk et al 2002). But this assumes a large number of fractions and a single
dose-response slope (γ50 for prostate tumours).So it is difficult to use this recipe for tu-
mours other than prostate and also for different fractions, especially hypofractionated
treatments. This study involves all the variables that the TCP-based margin would
depend on, namely number of fractions, γ50 and systematic and random uncertainties
with different levels of dose conformity as well.
There are several assumptions made in this work, including shift-invariance of dose
distributions, very high conformity of dose in the spherical dose distributions and a
uniform clonogen density inside the CTV. We consider two of these assumptions to
be worst-case scenarios thus allowing our conclusions to be safely extended to more
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realistic situations. The first pertains to our use of a constant clonogen density in the
GTV-to-CTV region where it will be lower than that in the GTV [106–109]. However,
overestimating the number of clonogens in the region which will be the most affected
by tumour displacement will lead to an overestimation of required margins, so in that
sense the margins derived in this work are conservative. Another assumption is the
high conformity of the spherical dose distribution. We realize this dose distribution
may be unachievable but here again any displacement will bring the clonogens to an
unrealistically low dose region. This will in turn increase clonogen survival and there-
fore reduce TCP further. The four-field box dose distribution was chosen to study the
effect of beam directions and significant incidental dose on the TCP.
The slope of the dose-response curve affects the importance of systematic and ran-
dom errors on TCP [110]. Our results show that it not only depends on geometrical
uncertainties and dose-response slope but also on the number of fractions and treatment
technique used. It is evident that random errors increase in significance for hypofrac-
tionated radiotherapy. For a small Σ and σ (1, 1) the margins are much smaller (near
zero) than the margin calculated according to the physical dose-based recipe [94]. In
this case, the variation of the margin with number of fractions and dose-response slope
is negligible. In the case of (1, 3) though Σ is less, it is interesting to note that the
margins for a very small number of fractions and a steep γ50 are even higher than the
margins calculated by physical dose-based recipe. This emphasizes the need to use a
larger margin for hypofractionated radiotherapy, particularly for tumours with steep
dose-response slope, such as in SABR of lung tumours. For a large Σ and a small σ
(3, 1) the margins increase gradually with fractions and γ50 but they are much larger
than (1, 3) denoting that a large Σ always require a larger margin than for the same σ.
The margins required for ≤ 1% loss in TCPpop are in general significantly lower than
the ones calculated by physical dose-based recipe. It has also been recently shown by
Yoda et al [111] that the coefficient of the systematic component in van Herks margin
recipe is smaller than the one used by van Herk et al [94] for anisotropic systematic
uncertainties, which shows that the margins for anisotropic systematic uncertainties is
smaller than the ones calculated by van Herk et al (vanHerk2000).
For the four-field dose distribution the margins are <1mm for Σ and σ (1, 3) and
(1, 1) mm. This indicates that for less conformal treatments the incidental dose outside
the target volume will take care of small geometric uncertainties with out needing any
extra margin around it. The margins for other combinations of Σ and σ are lower than
those required for the spherical dose distribution. This leads to the conclusion that
margin selection strongly depends on the conformity of the prescribed dose, number
of beams and their directions which determines the dose spread outside the PTV, in
particular in situations where uncertainties are not isotropic. The relationship between
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the level of the incidental dose and the number of beams would also be interesting to
explore as it should affect the resulting incidental killing of clonogens. Jin et al have
shown that the distance between the 50% and prescription isodose level are in most
cases exceed 10 mm and this dose can be sufficient to kill the relatively small number of
clonogens in the GTV-CTV region [54]. Thus, the inclusion of a non-uniform clonogen
density in the GTV-CTV region would reduce the required margins even further. Jin
et al (2011) have derived a margin recipe as a function of geometric uncertainties and
variation of clonogen in the GTV-CTV region, this margin being directly added to the
GTV rather than the CTV. These margins are substantially (few mm) smaller than
the TCP loss-based and physical dose-based margins but reliable clinical data on the
clonogen variation in the GTV-CTV region is scarce and yet crucial if these results are
to be used clinically. On the other hand, parameters for TCP calculation for certain
tumour types are available in the literature. It is worth mentioning here that the TCP
model parameters were fitted to the dose distributions derived using the dose calcu-
lation algorithms in the treatment planning systems (TPS) and the observed clinical
outcomes. TCP parameters published in the literature assume that the dose distri-
butions calculated by the dose calculation algorithm in the TPS represent the actual
dose delivered to the tumour, which is valid. In reality the difference between the doses
calculated and delivered to tumours differ because of the limitations in the accuracy of
the dose calculation algorithms and also due to the geometric uncertainties in the treat-
ment delivery, which the dose calculation algorithms do not account for. Differences up
to 20% were reported while using TCP parameters inconsistent with the dose calcula-
tion algorithm [112]. Thus the TCP parameters require a refit to the observed clinical
outcomes using the dose distributions actually delivered to tumours which accounts
for geometric uncertainties. TCP based margins are more robust if the assumptions
on which they are based are valid, namely TCP parameters, accurate definition of CTV.
The dependence of TCP loss on tumor volume was found to be weak. In general, the
relative loss in TCP was greater for smaller tumors, but depends on the TCP parameters
used and the prescription dose and degree of geometric uncertainties. From the results
of an average dose-response slope (γ50), 20 fractions and 3 mm standard deviation of
both systematic and random uncertainties the variation in TCP loss (relative to static
tumour) ranged from 1.7% to 0.6%.
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Chapter 5
Effect of clonogen distribution on
tumour control probability
5.1 Introduction
A typical planning approach is to expand the CTV with a PTV margin such that CTV
will always receive the prescribed dose even in the presence of geometric uncertainties.
As mentioned before, general objective of treatment planning is to achieve a uniform
dose distribution inside and as low as possible outside the PTV. This assumes that
there are no clonogenic cells outside the CTV and every voxel inside the CTV has the
same number of clonogenic cells. However, studies have shown that the probability of
clonogenic cell density decreases from the GTV boundary and it may not be limited to
the CTV [14, 58, 59, 113]. In such a scenario, relatively lower density clonogenic cells
can be eradicated with a relatively less amount of dose than that is usually considered
tumoricidal. Thus the PTV margin can be reduced to limit the high dose more closer
to the CTV and the gradual dose fall off inside the reduced-PTV should be sufficient
to eradicate the low density clonogenic cells even in the presence of geometric uncer-
tainties (cf. fig1.4).
Treatment delivery accuracy can be greatly improved with IGRT techniques, thus
a smaller PTV margin can be used to account for smaller uncertainties in these tech-
niques. However, the reduced PTV margins should be treated with caution as the
accuracy of CTV definition (extent of clonogenic cells) becomes more and more impor-
tant in these situations [114]. In cases where large PTV margins are used (conventional
treatments), the uncertainty in the CTV definition can be taken care of by the large
PTV margin whereas the probability of missing the CTV is higher in IGRT due to
smaller PTV margins used. This is illustrated in figure 5.1.
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Figure 5.1: Illustration of a scenario where CTV is inaccurately delineated and its
consequences in a)conventional radiotherapy with large PTV margin and in b)image-
guided radiotherapy where smaller margins are employed
Another important point to be considered regarding the distribution of clonogenic
cells is the effect of extra-CTV tumour islets on treatment outcome. Low density tu-
mour islets outside the CTV are not easily detectable by current imaging modalities. In
some cases the extra-CTV tumour islets can be eradicated by the incidental dose out-
side the PTV due to the nature of photon beam irradiation, whereas in other cases they
may be missed. Witte et al [65] have shown in a multi-centric retrospective analysis
of prostate treatments that patients who had local failure had different beam orienta-
tions than others where the beams did not pass through the areas where microscopic
disease extension is expected. Thus the treatment outcome is highly influenced by the
probability of these extra-CTV islets being eradicated by incidental dose.
The work presented in this chapter briefly discusses three important issues on treat-
ment outcome using TCP modelling:
(a) Possible PTV margin reduction if the clonogen distribution in the GTV-CTV region
is found to be less than in the GTV
(b) Consequences of using small PTV margins in IGRT treatments where accurate
CTV extent is unknown
(c) Effect of extra-CTV islets and incidental dose on TCP
Due to time constraint, the work presented in this chapter is not complete but pro-
vides useful insights into the issues surrounding the PTV margins, clonogen distribution
and their effect on treatment outcome.
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5.2 Decreasing clonogen density in GTV-CTV region and
the required PTV margins
5.2.1 Material and methods
To study the effect of decreasing clonogen density distribution in the GTV-CTV region
on TCP and PTV margin, an exponential clonogen distribution with different degrees
of fall off from the boundary of the GTV is assumed. The clonogen density distribution
is calculated using equation 5.1. The radius of the GTV and CTV is 20 and 25 mm
respectively. The total number of clonogens in all the cases within the CTV is set
constant by adjusting the density of the clonogenic cells. The distribution of clonogenic
cells from the boundary of the GTV is shown in figure 5.2 for three different slopes.
For the slope factors of 0.5 and 1.0 the density is near zero at the boundary of the CTV
whereas it is considerably higher for slope factor of 3.0.
Figure 5.2: Exponential clonogen density distribution from the edge of the GTV in
normal (top) and semi-log (bottom) scales
ρcl(r) = exp(−r/s) (5.1)
where ρcl is the clonogen density, r is the distance from the edge of GTV and s is
the slope factor.
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TCP calculation inclusive of geometric uncertainties and clonogen density
distribution
A spherically symmetric dose distribution as discussed before is used for simulating
the effect of geometric uncertainties on TCP with an exponentially decreasing clonogen
density in the GTV-CTV region. Four different combinations of high and low system-
atic (Σ) and random (σ) errors were used for the simulations. The PTV margin was
varied from 0 (no PTV margin) to 10 mm. The prescription dose was selected to obtain
50% TCP for the static case in 20 fraction treatment. Average dose-response slope was
assumed for the TCP calculations (σα=0.07Gy
−1). The dose in each voxel in each
fraction is summed for the give Σ and σ for the entire course of treatment as described
in chapter 3. The voxel control probabilities (VCP) for each voxel is calculated from
the accumulated voxel dose values and their corresponding clonogen density (ρcl) from
the exponential function. The rest of the TCP calculation is performed similar to CTV
with uniform clonogen density distribution. The simulations were performed as men-
tioned in chapter 3 for different combinations of systematic (Σ) and random (σ) errors
namely (1,1), (1,3), (3,1), (3,3). Simulations were repeated until the standard error of
the mean population TCP (TCP ) is ≤0.15.
5.2.2 Results and discussion
The results showed a similar trend as observed for the uniform clonogen distribution
except the required margins for ≤1% loss in mean population TCP are considerably
smaller except for the slope factor of 3.0. Larger margins required for slope factor of 3.0
is due to the reason that more number of clonogens will be missed due to displacements
as the clonogen density is greater at the outer edge of the CTV compared to slope factors
of 0.5 and 1.0.
Table 5.1: Margins (mm) for ≤1% loss in TCP pop for different combinations of system-
atic and random errors (Σ, σ) compared with exponential decrease in clonogen density
from GTV and a uniform clonogen density in the CTV.
Slope (1,1) (1,3) (3,1) (3,3)
0.5 0.0 0.5 2.0 4.0
1.0 0.0 1.4 3.0 5.5
3.0 0.8 2.5 4.0 6.3
uniform density 1.8 3.5 5.0 6.3
However, for large geometric uncertainties (Σ, σ = 3mm) the margins with an
exponential and uniform distribution of clonogens are almost same. This shows that
geometric uncertainties are a dominant factor in deriving margins. This also highlights
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the importance of reducing geometric uncertainties in radiotherapy.
Figure 5.3: TCP pop vs PTV margin for Σ=1mm and σ=1mm, compared with uniform
clonogen density (UD) in the CTV
Figure 5.4: TCP pop vs PTV margin for Σ=1mm and σ=3mm, compared with uniform
clonogen density (UD) in the CTV
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Figure 5.5: TCP pop vs PTV margin for Σ=3mm and σ=1mm, compared with uniform
clonogen density (UD) in the CTV
Figure 5.6: TCP pop vs PTV margin for Σ=3mm and σ=3mm, compared with uniform
clonogen density (UD) in the CTV
5.3 Risk of using smaller PTV margins
To demonstrate the risk of using smaller PTV margins in IGRT treatments where CTV
extent is not precisely known, a cosine clonogen distribution is assumed. A cosine
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distribution is chosen because the density of the clonogens can be made zero at the
edge of the CTV whereas it is non-zero in a exponential case. The cosine distribution
is calculated using equation 5.2. The resulting distribution for GTV-CTV distances
of 5, 10 and 15 mm are shown in figure 5.7. Two different scenarios are assumed
a)Treatment where the systematic (Σ) and random (σ) errors are both 1 mm with
a PTV margin of 2mm as might be used with IGRT b)Conventional treatment with
standard imaging protocol with Σ and σ of 3mm with a PTV margin of 8 mm. A
GTV-CTV distance of 5 mm is assumed and the cosine clonogen density is calculated
for the corresponding voxels using equation 5.2.
ρcl(r) = cos(−r/d(pi/2)) (5.2)
where ρcl is the clonogen density, r is the distance from the GTV edge, d is the
distance between the GTV and CTV.The prescription dose for both scenarios were set
to achieve 50% for the static cases. Mean population TCP (TCP pop) was calculated
inclusive of geometric uncertainties as described previously. Later, the CTV size is in-
creased to 26, 27 and 28 mm. The PTV margins were kept same for both conventional
and IGRT treatments. The resulting TCP loss relative to the static case are shown
in figure 5.8.It is evident from figure 5.8 that the TCP loss is greater in IGRT treat-
ments with smaller margins if the CTV extent is inaccurate, whereas in conventional
treatments where large margins are employed the uncertainty in CTV definition can be
accounted by the PTV margins. For the conventional case for a 3 mm larger CTV the
TCP loss is ∼3% whereas it is ∼9% for the IGRT. The TCP loss in conventional case is
gradual but it is abrupt in case of IGRT. This demonstrates the importance of accurate
CTV definition to achieve high local control of tumour where smaller margins are em-
ployed. Heemsbergen et al [115] have shown that rectangular fields are associated with
lower risk of local tumour progression compared to patients treated with conformal
fields in high risk prostate patients. This raises the question whether the poorly known
microscopic disease is not defined accurately in the conformal fields or the microscopic
disease is incidentally eradicated by the large rectangle fields. In another study Witte
et al [65] have shown incidental dose in regions where microscopic spread could be
expected is found to be the reason in patients without local failure in high risk prostate
patients. It should be noted that the potential margin reduction using IGRT is limited
by the accuracy of the CTV definition. Accurately detecting microscopic disease is
impossible, for instance even positron emission tomography (PET) has a resolution of
5 mm whereas the microscopic disease can be much smaller than this. Thus, even with
the latest functional imaging it is impossible to detect microscopic disease accurately.
There are other issues with CTV definition such as inter and intra observer variation in
delineating the CTV. The same radiation oncologist will delineate the CTV differently
on the same CT image at different occasions. As mention in an editorial article by
75
Marcel van Herk [116] IGRT has the potential to greatly reduce the uncertainties in
treatment delivery but it cannot reduce the biological uncertainties. Hence, any margin
reduction should be carefully evaluated and smaller margins should be employed with
caution.
Figure 5.7: Cosine clonogen distribution in a CTV shell of 5, 10 and 15 mm radius
Figure 5.8: TCP loss for different CTV sizes in conventional and IGRT scenarios
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5.4 Extra CTV islets and TCP
To study the effect of extra-CTV tumour islets on TCP and dose-response curve an
anonymized prostate IMRT treatment plan with five fields is used. Figure 5.9 show the
chosen plan with axial dose distribution and the CTV. Five tumour islets were randomly
distributed outside the CTV within a margin of 3 cm. The diameter of the each islet
is 3mm. These values are taken from van Loon et al [63]. A random instance of five
islets distributed around the CTV is shown in figure 5.10. The clonogen density of each
islet is calculated using the exponential form given in equation 5.1 using the distance
between the centre of the islet to the closest edge of the CTV with a exponential factor
of 0.5. The prescription dose was rescaled to 32 Gy and the TCP was calculated using
an average dose-response slope (σα=0.07Gy
−1). The TCP calculation was repeated
10 times to get an average TCP by randomly distributing the islets. The dose was
then increased up to 102 Gy in steps of 5 Gy to obtain the dose-response curve with
extra-CTV islets. Obtained dose-response curves for both with and without islets are
shown in figure 5.11.
Figure 5.9: IMRT plan with axial dose distribution and the CTV used for simulating
the effect of extra-CTV islets on dose-response curve
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Figure 5.10: Randomly distributed islets outside CTV shown along with the CTV
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Figure 5.11: Dose-response curve with and without islets outside the CTV.
The dose-response curve observed with islets showed a normal sigmoid shape, how-
ever the dose-response curve with islets showed a biphasic sigmoidal shape (i.e. com-
bination of two sigmoidal curves). In some cases where extra-CTV islets are found, it
is possible to eradicate the islets by escalating the prescription dose which in turn will
increase the dose outside the PTV (incidental dose). If by chance these islets are in
the beam path ways close to the CTV, they can be killed by the incidental dose. On
the other hand, if these islets are found some where out of beam paths, 100% TCP
cannot be achieved by simply escalating the dose. This opens up a debate on how this
concern of microscopic disease affects other treatment modalities such as VMAT, Cy-
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berknife and proton therapies which have a much more conformal and have steep dose
gradients than conventional photon beam irradiation. VMAT treatments have a more
uniform dose fall off (spherically symmetric) than static field IMRT and hence VMAT
treatments are more likely to eradicate microscopic tumour islets within the vicinity of
the tumour. However, there are other factors such as number of beams, their gantry
angles, dose constraints and their priorities used in the optimization process which de-
cides the dose fall off in a given region in space. As far as Cyberknife is concerned, it is
mostly used for lower stage and well localized diseases. In such cases, the probability
of microscopic disease is very less and is of less concern for local control. Coming to
protons and other ion beam therapies which are more conformal and have the capa-
bility to produce steeper dose gradients than photon beams, the risk of lowering the
local control is higher compared to photon beam therapy if the CTV is not accurately
defined. Its too early to derive to a conclusion on this issue as there are too may factors
which determine the effect of microscopic disease on local control in different treatment
techniques. Therefore a much more detailed studies are required, either insilico simu-
lations or retrospective clinical analysis of these issues such as Heemsbergen et al [115]
and Witte et al [65]. Nevertheless, it is clear that higher conformal treatments require
greater attention to biological uncertainties than conventional treatments which has
taken care of these biological uncertainties up to some extent by generous PTV mar-
gins used. Dose escalation is also beneficial only if the microscopic disease is accurately
known.
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Chapter 6
4D Radiobiological modelling of
the interplay effect in
conventionally and
hypo-fractionated lung tumour
IMRT
6.1 Introduction
6.1.1 Lung motion
Lung is responsible for transporting oxygen from the atmosphere into the bloodstream
and carbon dioxide from bloodstream to the atmosphere, a process called as respira-
tion. Respiration is an involuntary action, however individuals can have control over
the frequency, displacements and breath hold. There are several other organs including
esophagus, liver, breast, kidneys, pancreas and prostate known to move with breath-
ing. Patients’ breathing patterns have been shown to vary in magnitude, period and
regularity from time to time (i.e., may be different between imaging and treatment
delivery) [117–120]). However, studies have shown that the respiration reproducibil-
ity can be improved by audio-visual biofeedback [119–121]. The magnitude of tumour
motion has been shown to be independent of tumour size, its location and pulmonary
functioning suggesting that tumour motion should be assessed individually for each pa-
tient [122]. There is an extensive list of publications which have reported lung motion
using numerous imaging modalities including ultrasound [123–125], CT [19, 126–128],
MR [129] and fluroscopy [130–136]. The findings of some of these studies are given in
table 6.1.
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Table 6.1: Range of lung motion observed in different studies in different parts of the
lung with mean (min- max) in mm (left blank where information was not reported)
Observer SI AP LR Imaging modality
Roos et al [19] (upper lobe) - 1(0-5) 1(0-3) CT
Roos et al [19] (middle lobe) - 0(0-5) 9(0-16) CT
Roos et al [19] (lower lobe) - 1(0-4) 10.5(0-13) CT
Barnes et al [131] (lower lobe) 18.2(9-32) - - fluroscopy
Barnes et al [131] (middle,upper lobe) 7.5(2-11) - - fluroscopy
Seppenwoolde et al [137] 5.8(0-25) 2.5(08) 1.5(0-3) fluroscopy
Sixel et al [134] (0-13) (0-5) (0-4) fluroscopy
Grills et al [135] (2-30) (0-10) (0-6) fluroscopy
Murphy et al [133] 7(2-15) - - fluroscopy
Chen et al [130] (0-50) - - fluroscopy
Plathow et al [129] (upper lobe) 4.3(2.6-7.1) 2.8(1.2-5.1) 3.4(1.3-5.3) MR
Plathow et al [129] (middle lobe) 7.2(4.3-10.2) 4.3(1.9-7.5) 4.3(1.5-7.1) MR
Plathow et al [129] (lower lobe) 9.5(4.5-16.4) 6.1(2.5-9.8) 6.0(2.9-9.8) MR
The results from the literature leads to the conclusion that every patient’s breath-
ing pattern is unique and no biomathematical models can predict the motion of lung
tumours prior to observing their motion. Many patient characteristics involved in
breathing of a particular patient such as quiet vs deep, chest vs abdominal and pa-
tient general health condition makes it unpredictable using mathematical models. It
should also be noted that most of the lung tumour displacements (with an exception
to Seppenwoolde et al [137] where the displacements are measured using implanted
gold markers) reported in the literature are measured using tumour surrogates such as
diaphragm motion or infrared markers placed on the patient chest or abdomen. The
displacements measured using surrogate markers do not correlate with the actual lung
tumour motion.
6.1.2 Respiration and interplay effect
Respiration-induced organ motion represents a serious challenge regarding the accuracy
of dose delivery in radiotherapy and its impact on clinical outcome. Lung tumours are
the most common tumours affected by respiration-induced motion, and local failure
(approx. 70% of the cases) is considered as a major cause of tumour-related death.
Studies have highlighted the importance of dose escalation for improving local control
in non-small-cell lung tumours (NSCLC) [138, 139]. Since intensity-modulated radio-
therapy (IMRT) has the potential to deliver higher doses with fewer normal tissue
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complications [140], IMRT is often used nowadays to treat lung tumours. Moreover,
hypofractionated treatments have been shown to result in better clinical outcomes for
medically inoperable early-stage lung tumours [57,141–143]. Better targeting accuracy
coupled with superior normal tissue sparing and higher dose conformality especially
with smaller treatment fields used in stereotactic treatments, allows clinicians to pre-
scribe extremely high doses in very few fractions (∼ 3). With the advent of image-
guided radiotherapy (IGRT) this type of treatment is becoming increasingly common
for lung radiotherapy. However in MLC-based IMRT delivery, the ‘interplay ’ between
the respiration-induced tumour motion and the movement of MLC leaves can result
in undesired motion artifacts in dose delivery [38, 144]. Consequently motion manage-
ment or correction techniques such as tumour tracking or gating have been suggested
for treating moving tumours with IMRT [145–148]. It should also be noted that lung
tumours have one of the steepest dose-response curves ( γ50 = 3.9) [104] which means
that a small change in dose results in a relatively large change in TCP. Although motion
management techniques are currently available, it may not be possible to use such tech-
niques for each patient either due to time or resource constraints. Thus it is important
to understand and quantify the effect of tumour motion in IMRT treatments i.e. the
‘interplay’ effect, in the absence of tumour tracking or gating. By quantify we mean
not only in terms of absorbed dose, a purely physical quantity, but more importantly
in terms of changes in the probability of local tumour control.
Several studies have investigated the effect of respiration-induced tumour motion on
IMRT treatments [38–45]. Jiang et al [39] have investigated the effect of interplay for
three different modes of IMRT delivery (step-and-shoot with 10 and 20 intensity levels,
sliding window) using a 0.6cc farmer chamber positioned at the centre of the tumour in a
moving phantom. They found that the mean dose to the moving tumour for all the fields
varies < 2−3%, but it could be as high as 30% for a single field. They have also shown
that the variation in dose is insensitive to the mode of delivery and the dose differences
due to interplay decrease as the number of treatment fractions becomes large (∼ 30).
This has been previously emphasized by Bortfeld et al [38] who showed by statistical
analysis that the mean dose to a moving tumour is insensitive to the delivery technique
and the standard deviation in dose for a 30-fraction treatment is generally < 1% of the
mean dose. However, the conclusion derived from point-dose measurements by Jiang
et al does not provide a complete picture of the interplay effect to the overall tumour
volume. Using 2D film measurements, Berbeco et al [149] have shown that the standard
deviation of the dose to a pixel inside the target volume can be as high as 2 − 4% for
single fraction treatments which correspond to stereotactic radiosurgery, although the
effect is reduced to 0.4-0.7% with 30 fractions. According to their measurements, the
maximum dose in the target varies < 1% while the minimum dose varies up to ∼ 6%.
This indicates that there could be considerable underdosage of the target volume even
for treatments with large number of fractions and the effect of interplay is significant
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for hypofractionated treatments. In a recent study by Zhao et al [150] in a 3 fraction
treatment, the results showed that the CTV could be considerably underdosed due to
the interplay effect in a Cyberknife treatment (Accuray, Sunnyvale, A). Furthermore,
Seco et al [151] have emphasized that reduced dose errors due to interplay effect in
many-fraction treatments will not apply to hypofractionated treatments.
While there are numerous studies addressing the issues of interplay effects in terms
of dose variation in the tumour, studies quantifying the clinical significance of these dose
variations are much rarer. Use of tumour control probability (TCP) as a metric would
provide a more valuable insight into the true significance of the interplay effect. As
mentioned by Niemierko [152], it would be interesting to know the clinical significance of
“x” amount of dose error and “y” amount of geometric error rather than mere variation
in the dose. Duan et al [42] have done a TCP analysis using a moving phantom and
found the TCP changes to be 2.3% and 4.3% for five- and single- fraction treatments.
However, the volume of the target used in their study is fixed (4.5 cm diameter sphere).
TCP values could significantly differ with the volume of the target even for the same
prescribed dose. Moreover, the TCP values provided were not calculated from a large
number of simulations, which raises concern over its applicability for a population of
patients.
In this study we use real patient datasets (3D CT image, plan information) covering
a range of tumour volumes (31cc to 172 cc) and a 4D dose model which provides 3D
voxel-by-voxel dose accumulation in the target volume inclusive of intrafraction organ
motion for step-and-shoot IMRT. This dose model takes into account the number of
treatment fractions, and radiobiological characteristics of lung tumours (γ50) for TCP
calculations. Though the dose computation algorithm is fairly simple, it is robust
enough to simulate the interplay effect in patient geometry. Moreover, a population
mean TCP (TCP pop) calculated from large number of simulations for each plan, is
used in this study and provides more statistically reliable TCP values. To obtain the
final dose to a particular voxel, the dose computation is performed for each fraction for
each beam segment. Inhomogeneity and scatter effects have been ignored to enable the
dose computation algorithm to accumulate the dose in each voxel over a fractionated
treatment in a reasonable time. The methodology described here is easy to extend to
other delivery techniques and could also be extended to account for scatter and for
heterogeneous tissue density using more sophisticated dose calculation algorithms such
as the one provided by Yang et al [153].
6.2 Material and Methods
A 20-fraction, 3-fraction and an extremely hypofractionated case of one-fraction treat-
ment were considered for the analysis. MUs for the single and 3-fraction treatment
were scaled from the 20 fraction plan to give a TCP around 50% (within the linear
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portion of the dose-response curve, in order to be in the steepest portion of the TCP
curve). This is around 8 Gy for single fraction, because the volume of target volumes
differed between patients. So a different dose was required or each patient to get 50
% TCP. Since we are not aiming for ¿90% TCP as achieved in SABR a low dose was
sufficient to achieve 50% TCP. A simulation is the total dose distribution obtained
by the accumulation of dose over the course of full fractionated treatment for a given
patient. Several simulations are performed per patient to calculate individual TCP.
6.2.1 Lung tumour motion simulation
Lung tumours tend to move in an elliptical path [137] rather in a one-dimensional
cranio-caudal (CC) direction. As mentioned before patient breathing pattern is complex
and varied from patient to patient. It can neither be predicted before observing the
breathing pattern of an individual patient’s breathing using either fluroscopy or 4D
CT. Hence a one-dimensional lung motion with a sinusoidal pattern in the CC direction
which is a good approximation is assumed here. The position of tumour at time t is
given by equation 6.1.
P (t) = Asin(wt + φ) (6.1)
where A is the peak deviation from the centre position of the tumour, w the angular
frequency and φ is the phase in radians at which breathing starts.
A clockwise-delivery is assumed to map the tumour position for each beam and
segment. Since breathing is involuntary and uninterrupted while leaves change their
position to the next segment or gantry moves to the next beam angle, the time elapsed
during these processes is accounted for while calculating the tumour position for each
segment for the given beam angle. A gantry speed of 60s for full rotation and a
time duration of 1s between segments is assumed. Even though breathing motion
is continuous, dose calculation is done using a discretized (1 position/segment) time-
averaged position P (t) using equation 6.2. The parameters used for the tumour motion
calculation are given in table 6.2. The range of tumour displacement in the cranio-
caudal direction reported in the literature ranges from 4.3 [129] to 18.2 [131] mm,
hence an average of these which is close to 10 mm is used in this study. However, this
can be varied in the model to simulate the real patient breathing pattern if known.
t =
tstart + tend
2
(6.2)
where tstart and tend are the start and end time for the given segment. If the
segment has MU greater than 50 (corresponds to 1 respiratory cycle for the breathing
parameters and doserate assumed), the dose is calculated by splitting the segment every
50 MU.
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Table 6.2: Parameters used for motion simulation
Parameter value
Amplitude (A) 10 mm
Period (T ) 5 s
Dose rate 600 MU/min
Segment interval 1 s
Gantry speed 0.166 s/degree
The field arrangement for a representative lung IMRT plan is shown in 6.1. Split-
ting of beam into several segments for dose calculation including tumour intra-fraction
movement is shown in figure 6.2. The beams are first sorted in a clockwise direction.
Figure 6.1: Beam arrangement for a four-field IMRT plan with CTV and PTV contours
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Figure 6.2: Mapping of mean tumour position P (t) (indicated with a cross marker) for
each segment for beam LAO. The green and red markers indicate beam’ on’ and ’off’
respectively.
Figure 6.3: Mapping of mean tumour position for beam RPO
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Figure 6.4: Mapping of mean tumour position for beam RLO
Figure 6.5: Mapping of mean tumour position for beam RAO
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6.2.2 DICOM RT Plans
An in-house developed software is used to read the DICOM objects including CT,
RT structures, RT dose, and RT plans. Three step-and-shoot IMRT plans generated
using Eclipse’s Dose-volume optimizer (DVO)(Varian Medical Systems, Palo, Alto)
and three using Pinnacle’s Direct machine parameter optimization (DMPO) (Philips
Medical Systems, Madison) in a 6MV Varian 2100C/D with 120 leaf Millennium MLC
are used for the analysis. Default number of 10 intensity levels is used for the Eclipse
IMRT plans and the default value of 50 maximum number of total segments for the
plan was used in Pinnacle’s DMPO. The prescription dose was 55 Gy in 20 fractions for
all the plans and the dose-volume constraints for the target and critical structures were
set according to the clinical protocols in use at our centre. The PTV margin was 1 cm
in all directions which is sufficient to account for 2 cm peak-to-peak tumour motion in
the CC direction.
6.2.3 Radiological path length calculation
Ray tracing is widely used in computer graphics for virtual reality rendering. The same
concept is used in radiotherapy applications for calculating the exact radiological path
length (RPL). A patient 3D model is generally obtained from a set of greyscale 2D CT
slices. The greyscale values which represent Hounsfield units (HU) of the voxels can be
used to calculate the RPL by using the relationship between HU and relative electron
density (RED). The HU is defined in equation (6.3).
HU =
(µtissue − µwater
µwater
)1000 (6.3)
where the µtissue and µwater are the linear attenuation coefficient of tissue of interest
and water respectively.
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Figure 6.6: Relationship between HU and RED
Siddon’s [154] ray tracing algorithm is widely used in radiotherapy for calculating
RPL. A class named “RayTracer” has been developed for calculating the RPL based
on Siddon’s raytracing algorithm in Biosim. The relationship between HU and RED is
shown in figure 6.6(values are taken from the Pinnacle TPS for the CT scanner used
at our institute).
The raytracing algorithm treats a 3D CT image array as a set of orthogonally
placed parallel planes with uniform spacing as shown in figure 6.7. By finding the
ray line intersections in [X,Y,Z] planes, the voxel indices [i,j,k ] through which the ray
passes can be obtained. The length through the ray passed is given by RPLvoxel =
lengthvoxel ∗ REDvoxel. The total RPL for a ray vector can be obtained by summing
the individual voxel RPLs through which the ray passes.
90
Figure 6.7: Raytracing through a set of orthogonal planes. Though the CT image is 3D,
for the sake of simplicity only a 2D depiction is shown here. The red squares represent
intersection with vertical and the green squares represent intersection with horizontal
planes.
A ray can be parametrically represented as shown in equations (6.4).
x = x1 + α(x2 − x1) (6.4a)
y = y1 + α(y2 − y1) (6.4b)
z = z1 + α(z2 − z1) (6.4c)
{x1, y1, z1} and {x2, y2, z2} are the position of the ray at source and the centre
of the voxel of interest. α (not to be confused with the radiobiological term) is the
distance traveled divided by the source-to-voxel distance. Now the image dataset can
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be expressed in terms of α as shown in equation (6.5). Capital letters (X,Y,Z) indicate
plane indices and dx, dy, dz represent voxel spacing in the x,y and z axes. {x0, y0, z0}
are the plane indices at (i, j, k) = 0.
Xi = X0 + idx (6.5a)
Yj = Y0 + jdy (6.5b)
Zk = Z0 + kdz (6.5c)
Using equations (6.4) and (6.5) the α value at a ray-plane intersection can be
calculated. Substituting (6.5) in (6.4) for x, the α value at a plane index can be
calculated as shown in equations (6.6).
αx(i) =
X0 + idx − x1
(x2 − x1) (6.6a)
αy(j) =
Y0 + jdy − y1
(y2 − y1) (6.6b)
αz(k) =
Z0 + kdz − z1
(z2 − z1) (6.6c)
Equation in (6.6) can be recursively written as shown in (6.7).
αx(i) = αx(i− 1)∆αx (6.7a)
αy(j) = αy(j − 1)∆αy (6.7b)
αz(k) = αz(k − 1)∆αz (6.7c)
Using (6.7) α can be calculated for all ray-plane intersections from the source and
the target voxel. These are calculated individually for each axis and the set of α is
stored as an array as shown in equation (6.8).
{αx} = {αx(imin)..............αx(imax)} (6.8a)
{αy} = {αy(jmin)..............αy(jmax)} (6.8b)
{αz} = {αz(kmin)..............αz(kmax)} (6.8c)
where “min” and “max” are the first and last intersections of the ray with the
orthogonal planes. Each term in the sets corresponds to a particular plane. Intersection
of the ray will the voxels can be found from the merged dataset {α} which would become
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{α} = {αmin,merge[{αx}, {αy}, {αz}], αmax} (6.9)
Two consecutive terms in {α} is associated with entering and leaving a voxel. Thus
the length traveled in a voxel is given by (6.10).
l(m) = [{α}(m+ 1)− {α}(m)]d12 (6.10)
where l(m) is the length traveled in voxel “m” and d12 is the distance from source
to the target voxel calculated using equation (6.11).
d12 =
√
(x2 − x1)2 + (y2 − y1)2 + (z2 − z1)2 (6.11)
The voxel indices through which the ray passes can be calculated using the α values
as shown in (6.12)
i(m) =
[
x1 + αmid(x2 − x1) −X0
dx
]
(6.12a)
j(m) =
[
y1 + αmid(y2 − y1) − Y0
dy
]
(6.12b)
k(m) =
[
z1 + αmid(z2 − z1) − Z0
dz
]
(6.12c)
where αmid can be calculated as
αmid =
[{α}(m) + {α}(m− 1)
2
]
(6.13)
The RPL is finally calculated using equation (6.14), where ρ is the relative electron
density of the voxel.
RPL = d12
m=n∑
m=1
ρ[i(m)j(m)k(m)]({α}(m + 1)− {α}(m)) (6.14)
6.2.4 Dose calculation to a moving target
The field and MLC details are defined for zero degree gantry angle in machine coordi-
nate system irrespective of the beam angle used in the DICOM RT plan whereas the
RT structures are defined in patient coordinate system. The source position, segment
and field shapes were first generated for the zero degree gantry angle in the patient
coordinate system and then transformed using a 4x4 transformation matrix according
to their respective gantry, collimator and couch angles (α, β, γ) as shown in equation
6.15.
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(6.15)
Where {x0, y0, z0} and {xt, yt, zt} are points for zero degree gantry and transformed
according to their corresponding collimator ,gantry, and couch angles (α, β and γ )
respectively. Since all the beam objects like jaw, gantry, collimator, MLC rotates about
the isocenter and not the image (CT) origin, a translate-rotate-translate approach,
where all the beam objects are translated to the origin, rotated and translated back
to the isocenter, is used for all transformations.The target structure of interest (CTV)
is divided into voxels of 3x3x3 mm3. Each MLC segment outline (ψ) is generated as
mentioned before using the leaf position details in the DICOM RT plan. A sufficiently
long ray is traced from the source position through each target voxel and a ray-segment
intersection check is performed as depicted in figure 6.9. Depending on whether the
ray is inside the segment or not and how close it is to the segment edge, the dose
to the target voxel is calculated using equations 6.16-6.21. The distance between the
segment edge and ray is calculated at the isocenter plane as shown in figure 6.10. A
linear penumbra model is used for the dose calculation. The radiological path length is
calculated using Siddon’s raytracing algorithm [154] assuming uniform water equivalent
density inside the patient.Dose-per-segment method is used, so that target voxels can be
shifted for each segment to mimic organ motion and the calculated doses in individual
voxels are summed for all segments and beams for all fractions. Since the starting phase
of breathing for a particular fraction is unpredictable, a random phase-shift is applied
to the organ motion calculation for each fraction in the interval 0 ≤ φ ≤ 2pi. Figure 6.8
shows the variation of breathing traces due to nature of treatment startup at random
phases.
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Figure 6.8: Random phase shift at different fractions
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Figure 6.9: Ray-segment intersection, where ray ST contributes to voxel T1 but not to
T2
D(x, y, z) =
f=n∑
f=1
i=nb∑
i=1
j=ns∑
j=1
MUi,jFi,j (6.16)
where nb and ns are the number of beams and segments in beam i and n is the
number of treatment fractions. Fi,j is the dose correction factor for segment j in beam
i. Fi,j is calculated using equation 6.17 using the tissue-maximum ratios (TMR) values
taken from BJR25 [92] for a 6 MV linac. Since scatter is ignored in our dose model the
output factor is set to unity for all segments. the TMR values for corresponding field
sizes at a water equivalent depth (wed) is used.
Fi,j = TMR(wed(x, y, z), ESF ) ∗ cf ∗ SADfactor ∗ pf (6.17)
Where ESF is the equivalent field size calculated using equation 6.18, cf is the
calibration factor of the linac (1 cGy/MU), pf is the penumbra factor.The SAD factor
and the pf are calculated according to equations 6.19 and 6.20 respectively.
96
ESF =
2ab
(a+ b)
(6.18)
SADfactor =
(
1000
1000− (dIC − d)
)2
(6.19)
dIC is the depth of isocenter and d is the water equivalent depth of voxel of interest
in mm.
pf =

1, if ST ∈ ψ & dedge ≥ 5mm
pfin, if ST ∈ ψ & dedge < 5mm
0.016, if ST 3 ψ & dedge ≥ 5mm
pfout, if ST 3 ψ & dedge < 5mm
(6.20)
pfin = 1.0− ((5.0− dedge)/10.0) (6.21)
pfout = 0.5− (dedge/10.0) (6.22)
Figure 6.10: MLC outline at the isocenter level with points inside (P1) and outside
(P2) the segment. dedge is calculated from the closest edge of the segment to the ray
.
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Figure 6.11: Nassi-Shneiderman diagram of the simualtion process
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Figure 6.12: Dose color wash for a 5x5 cm2 anterior field with MLC
Figure 6.13: Percentage depth dose calculated in a water phantom for 10x10 cm2
fieldsize
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Figure 6.14: Cross profile calculated in a water phantom for 10x10 cm2 fieldsize
Figure 6.15: Dose distribution calculated with the simple beam model in a spherical
VOI
The dose distribution calculated using the beam model in a spherical volume-of-
interest is shown in figure 6.15 with imported structures and beams and the corre-
sponding cumulative and differential DVH for CTV in figure 6.17.
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Figure 6.16: Cumulative and differential DVH calculated for static CTV using the
simple beam model (please note the expanded scale in x-axis)
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Figure 6.17: Representative cumulative DVHs for 20 fractions and 1 fraction with inter-
play effect and their corresponding static case (shown with marker) for a representative
case.
6.2.5 Population TCP calculation
The population mean TCP (TCP pop) is calculated using the enhanced “Marsden”model
[71] as shown in equation 6.23. σα value of 0.037 which corresponds to NSCLC is
used [112]. α value of 0.30 Gy−1 and a clonogen density (ρcl) is set to 1E7 cells/cc.
The number of simulations were repeated until the standard error is ≤ 0.20.
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TCP pop =
1
n
n∑
1
TCP (6.23)
where n is the number of simulations.
6.3 Results and discussion
The TCP values for 20 and three fraction treatments are calculated based on the final
accumulated dose (Dvoxel) in each individual voxels over the course of treatment. This
assumes that each voxel receives a dose of Dvoxel/n each fraction, which is an approxi-
mation. In fact the dose to each voxel for each fraction in the presence of the interplay
effect will be different from the mean Dvoxel/n [155]. Thus the biological effect of non-
uniform dose is also a concern in interplay effect where some voxels receive very less
dose while some other voxels receive a very high dose in a particular fraction. However,
for a fractionated treatment Bortfeld et al [38] have shown that the radiobiological
differences are negligible for tissues with high α/β ratio and the differences are large
only for tissues with lesser α/β ratio. Since tumours have a high α/β ratio(10 Gy)
and the treatments are fractionated, the effect of non-uniform dose to voxels on TCP
should be negligible. This concern disappears for single fraction treatments.
The spatial variation of dose (accumulated dose) due to interplay effect is shown
in figure 6.18 for one plan used in the study. For comparison, the dose for the single
fraction plan is set equal to the 20 fraction plan (i.e., the dose that produces 50% TCP
in the 20- fraction plan). In this case a significant underdosage can be observed for
the single fraction plan but this just for one treatment and could be opposite for other
treatments.
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Figure 6.18: Axial, sagittal and coronal dose difference comparison on isocentre plane
for 20-fraction and 1-fraction treatment with the static case. Blue represent no change
in the dose and darker red represents greater difference with the static case.
The percentage variation in population minimum (%D¯min), maximum(%D¯max) and
mean(%D¯mean) dose relative to the static tumour are shown in figure 6.19. The mean
values %D¯min, %D¯max, %D¯mean are calculated from the mean of the individual plan
values. These values are given in table 6.3 along with their standard deviations. The
population mean of %D¯min, %D¯max and %D¯mean are < 1% for the 20 and three frac-
tions treatments but larger for the single fraction treatments. However, the standard
deviation of the three fraction treatment is considerably more than 20 fractions treat-
ment, which indicates that individual patients will experience larger variations in dose
values for a three fractions treatment compared to 20 fractions treatment. The stan-
dard deviations for the single fraction treatments are even higher than that of three
and 20 fractions treatment. This very well corroborates the finding of Seco et al [151],
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who showed that reduced dose errors in many-fraction treatment will not work for
hypo-fractionated treatments. Although the effect of interplay on dose variations for
conventionally and hypofractionated treatments provides some understanding on the
nature of interplay effect, it is more useful to know the clinical significance of these dose
variations. Obviously for tumours, TCP will be a more meaningful indicator of clinical
outcome. The variation in TCP due to these dose variations caused by interplay effect
is shown in figure 6.21.
Figure 6.19: % change in population minimum, maximum and mean dose for 20, 3
and 1 fraction treatments. The values shown are average (obtained through several
runs of simulation for each plan) change in dose values. The error bars represent mean
standard deviation obtained from individual standard deviations
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Table 6.3: Percentage variation in population %D¯min, %D¯max and %D¯mean dose rela-
tive to the static tumour with standard deviations for different fractions.
Fractions %D¯min %D¯max %D¯mean
20 -0.33±0.59 -0.71±0.51 -0.76±0.36
03 -0.56±1.10 -0.96±0.97 -0.26±0.68
01 -1.95±1.39 -0.30±1.06 -1.05±0.98
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Figure 6.20: % TCP change compared to static tumour for 20, 3 and 1 fraction treat-
ments.
As shown in figure 6.20, the variation in TCP for 20 fractions treatment with in-
terplay effect is almost equal to the TCP value for the static tumour. This shows that
for treatments with large number of fractions, the dose errors will be small and thus
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the effect of interplay on TCP is negligible. This is mainly due to the underdosing and
overdosing of same voxels in different fractions (with many fractions) which lead to the
convergence of voxel doses similar to the static case. The degree of variation in dose
and TCP between patients for a given fractionation differs strongly as reported by Rao
et al [156], which indicates that the effect of interplay is dependent on the shape of the
tumour as tumours which are larger in the cranio caudal axis will experience greater
impact of interplay. In addition to that the fluence pattern is unique for each beam and
the gradient of the fluence will have a strong impact on the interplay, with the effect of
interplay increasing with the gradient of the beam fluence. But a large variation can
be observed for 3 and single fractions, mostly in the negative direction. It is interesting
to note that few patients could gain from the interplay effect as a result of a majority
of the voxels being overdosed, thus also increasing the TCP. However, it is impossible
to find out this small percentage of patients who would benefit from interplay effect
in reality. Though the TCP loss is unacceptably high for single and 3 fraction treat-
ments, it’s within acceptable limit (∼1%) for the 20 fractions treatment. The mean
of the population average TCP values calculated for each patient (TCP pop) provides a
general idea on how the interplay affects TCP pop. The TCP pop is shown in figure 6.21
for six plans for different fractionations along with the mean of all plans. As with the
standard deviation of the dose values, the standard deviation of the TCP pop are also
significantly different from the static case for the hypofractionated and single-fraction
treatments. This indicates that individual patient TCP values will experience large
variations in hypofractionated treatments compared to the static tumour. This can
be observed from figure 6.21 that in conventional fractionation the effect of interplay
on TCP pop is very marginal or within acceptable limit (−1.05 ± 0.39%), but for hy-
pofractionated and single fraction treatments such as radiosurgeries it is considerably
high, namely −2.82±1.68% and −3.95±2.84% respectively. This clearly indicates that
motion management methods are inevitable for hypofractionated treatments to avoid
significant loss in population TCP (though a small percentage of patients would benefit
from interplay effect) for IMRT of lung treatments. In contrast to our findings, Ong
et al [157] found that for single fraction RapidArc treatments the difference in dose
to the tumour is not significantly higher. However, these findings were based on 2D
dose measurements with films in the coronal plane which will not provide a complete
picture of the effect of dose to the tumour including interplay. While hypofractionated
treatments are subject to a lot of variability in the dose delivered to a moving tumour,
their increased delivery time (due to higher dose per fraction) makes the dose delivered
over many breathing cycles. Delivery of dose by each segment over multiple breathing
cycles would cancel out the dose differences which takes place across multiple fractions
for conventional treatments. This effect can reduce the dose errors up to some extent
in hypofractionated and single-fraction treatments where higher doses are delivered per
fraction.
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Figure 6.21: % TCP change for 20,3 and 1 fraction treatments with standard deviation.
The effect of dose rate on TCP due to interplay is studied for single fraction treat-
ments with 300 and 600 MU/min. The results are shown in shown in figure 6.22. From
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the figure, it is evident that dose delivery over multiple breathing cycles by reducing
the dose rate would reduce the interplay effect. On an average the TCP reduction due
to interplay effect was reduced ∼ 1.5% with 300 MU/min compared to 600 MU/min.
This indicates that reduced dose rate is beneficial for treating moving targets while
no motion management techniques are used. A similar finding has been reported by
Court et al [158] using a 2D ion chamber matrix for various dose rates in dynamic
IMRT plans.
Figure 6.22: Effect of dose rate on interplay for a single fraction treatment with standard
deviation.
As in other studies there are several assumptions made in this study.It should be
noted that real patient’s breathing is very different from the sinusoidal assumption. In
fact the breathing may continuously change amplitude and period making it is difficult
to model mathematically [159]. Another important point is that the lung tumour is
surrounded by a tissue of lower density and the density of this spongy tissue may vary
continuously during breathing which could have significant effect on the dose delivered
to the tumour. Further, the inhomogeneity and scatter corrections are ignored in this
study, which would actually influence the results slightly but the trend of the results
should remain same. As mentioned by Duan et al [42] the random positioning errors
during each fraction (isocenter offset, which would give actual position of segment
relative to the tumour position) should be accounted in order to study the exact dose
delivered to the tumour inclusive of interplay effect.
Though the dose model presented in this work does not account for scatter and
inhomogeneity, the methodology presented here to simulate the interplay effect can be
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easily extended to account for scatter and tissue inhomogeneity. Moreover systematic
and random errors can be incorporated into the simulation as the final displacement
of target voxels will be the sum of the three vectors namely, systematic, random and
cranio-caudal shifts. This model can also be used for dynamic treatments as well. The
simulation time to obtain the TCP pop with a reasonable standard error can be greatly
reduced by calculating the dose for some fractions (∼ 50) individually with random
phase-shifts and add them randomly (by randomly choosing the required number of
fractions from the 50 fractions) to get the final accumulative dose for n fractions.
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Chapter 7
Conclusions
Margins based on TCP is found to be lesser than dose-based recipes except for hy-
pofractionated treatments and tumours with steep dose-response curve. The margins
are also found to be dependent on dose-response curve and number of treatment frac-
tions. For the hypofractionated treatments, the effect of random errors too become as
detrimental as systematic errors as the assumption of dose blurring of random errors is
not valid for treatments with fewer fractions. The margins required based on TCP loss
is studied for spherical and four field dose distribution. For the four field treatment
with small geometric uncertainties (Σ, σ = 1 mm) and large number of treatment frac-
tions the margins are close to zero, but this assumes the CTV is accurately defined.
Comparison of the results with the widely used van Herk recipeet al [52] revealed that
dose-based recipes overestimate the margins for tumours with shallow dose-response
curve and underestimates for tumours with steep dose-response curve and hypofrac-
tionated treatments. The dose conformity was also found to have a strong influence on
choice of margins irrespective of tumour radiobiological characteristics.
The Monte Carlo method to simulate geometric uncertainties presented in this
thesis and the software framework developed can simulate the effect of geometric un-
certainties for a given plan with additional parameters such as number of fractions,
tumour radiobiological characteristics and estimates of systematic and random errors.
Implementation of such a method into treatment planning systems would be a great
tool to determine the margin sufficiency for a given plan with the dose distribution and
the radiobiological characteristics for the tumour of interest. Although the TCP based
margins are found to be smaller than dose based recipes, careful attention should be
paid to the biological uncertainties in the target volume such as the microscopic disease
extension, where they are present, what density it is of. The margin determination in
this thesis assumes that the microscopic disease is well contained with in the CTV.
In case the extent of CTV is not accurately known then the margin reduction would
increase the risk of local failure. However, if the knowledge of microscopic disease is
known from microscopic analysis of surgical specimen, reduced margins could be used
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which will greatly improve the therapeutic ratio.
Knowledge of microscopic disease is poorly known and is one of the major limit-
ing factor in harnessing the full potential of IGRT. It is also shown in chapter 4 that
patients with tiny tumour islets present around the tumour (which can only be de-
tected by microscopic analysis) does not benefit from dose escalation. The impact of
these microscopic disease on various treatment techniques such as VMAT, Cyberknife,
Tomotherapy and protons is not clearly known. Hence, employing smaller margins
is always associated with an increased risk of missing the tumour. Clinical trials are
needed to validate the influence of these factors on tumour control. Margin determina-
tion should be evidence based rather than just technology driven as all the uncertainties
in radiotherapy is not know.
Respiration induced tumour motion and the interplay between MLC movement is
found to have negligible impact on TCP for conventionally fractionated treatments.
However, it found to have substantial impact on hypofractionated and single frac-
tion treatments such as streotactic ablative radiotherapy and streotactic radiosurgery.
Hence motion management techniques such as tumour tracking or gating should be
used to maintain TCP loss within acceptable limits. The impact of dose rate is also
studied for two different dose rates namely 300 and 600 MU/min for hypofractionated
treatments and using a lower dose rate is found to mitigate the effects of interplay.
Hence, when no motion management techniques are used a reduced dose rate can be
used to minimize the impact of interplay. One of the major limitations of the dose
model presented in this thesis is that it does not account for scatter and tissue hetero-
geneity which are dominant in lung radiotherapy. However the results are compared
to the dose distribution of the static tumour computed from the same dose model and
hence the differences should be minimal. But the dose model is flexible to account for
these effects and the patient’s real breathing can be used instead of a sinusoidal wave
form.
7.1 Future work
Margin determination studied in this thesis assumes either highly conformal symmetri-
cal or a four field dose distribution, which are far from real dose distributions achieved
in the clinic. Margins are also found to be very much dependent on dose conformity
and the beam orientations. It would be very useful to determine margins for a given
planing protocol including beam orientations, dose conformity, tumour radiobiological
characteristics with the known systematic and random errors for the given treatment
using the Monte Carlo method presented in this thesis. This can be achieved by gen-
erating plans with different margins and to find the TCP loss for each plan. By doing
this for different geometric uncertainties and tumour types for each technique would
enable us to generate a lookup table of PTV margins.
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The impact of microscopic disease on tumour control is complicated and less stud-
ied as mentioned before. As we move towards higher and higher conformal treatments,
the importance of accurate target volume definition increases. If the target definition
is not accurate the benefit of these sophisticated and highly expensive treatments are
of not much use. The effect of microscopic disease in this thesis is studied only in the
phantom geometry assuming an exponential clonogen distribution and randomly dis-
tributing the tiny tumour islets outside the CTV. In reality, dose distribution resulting
from treatment plans depend on numerous factors such as treatment technique, dose
constraints, delivery method (fixed or rotational). Hence the amount and distribution
of the incidental dose is different for different techniques. The effect of microscopic dis-
ease on different techniques has not been reported and poorly understood. One reason
for lack of such studies is that it requires precise knowledge of the clonogen distribution
or the number of islets and their location, which can be obtained only through exten-
sive microscopic analysis of surgical specimens. Nevertheless, assuming an exponential
clonogen distribution and using the dicom datasets of few patients treated by various
treatments such as static field IMRT, VMAT, Cyberknife and proton therapies with
the dose distribution obtained from treatment planing systems would shed light on the
importance of accurate CTV delineation in image guided conformal radiotherapy.
The interplay dose model presented assumes several simplifications in order to speed
up the calculation time. It also assumes a sinusoidal breathing pattern although the
real breathing pattern is slightly different and also varies from patient o patient. It is
possible to obtain the breathing pattern of an individual patient either using a respira-
tory position management system (RPM) or a 4D CT. The model also doesn’t account
for dose scatter or heterogeneities. However the model presented in this thesis is flex-
ible enough to account for these. Methods used in IMRT dose verification algorithms
can be used to account for scatter and tissue heterogeneities with slight modification
of the current dose model hence it is also based on ray tracing. Moreover, the patient’s
breathing pattern with the actual amplitude and frequency can be used instead of a
sinusoidal pattern. These modifications will greatly improve the accuracy of the dose
model to quantify the effect of interplay on dose distribution and TCP. The dose model
can also be extended to rotational delivery techniques such as VMAT/RapidArc.
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